

# Non-motor features of Parkinson disease

Anthony H.V. Schapira<sup>1</sup>, K. Ray Chaudhuri<sup>2</sup> and Peter Jenner<sup>3</sup>

**Abstract** | Many of the motor symptoms of Parkinson disease (PD) can be preceded, sometimes for several years, by non-motor symptoms that include hyposmia, sleep disorders, depression and constipation. These non-motor features appear across the spectrum of patients with PD, including individuals with genetic causes of PD. The neuroanatomical and neuropharmacological bases of non-motor abnormalities in PD remain largely undefined. Here, we discuss recent advances that have helped to establish the presence, severity and effect on the quality of life of non-motor symptoms in PD, and the neuroanatomical and neuropharmacological mechanisms involved. We also discuss the potential for the non-motor features to define a prodrome that may enable the early diagnosis of PD.

## Bradykinesia

Abnormal slowness of movement.

## Rigidity

Stiffness and increased tone of muscles.

## Levodopa

Orally active dopamine precursor.

Parkinson disease (PD) is a progressive neurodegenerative disorder that involves multiple neurotransmitter pathways within the brain and autonomic nervous system that in turn are associated with a range of clinical features (TABLE 1). The diagnosis of PD is currently dependent on the presence of motor deficits including bradykinesia, rigidity and tremor, usually manifesting unilaterally or at least asymmetrically<sup>1</sup>. The motor features are predominantly a consequence of the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), and the symptomatic therapy used in PD currently focuses on dopamine replacement strategies. Advancing focuses and increased doses of levodopa result in the development of motor complications that are characterized by wearing off periods and off periods, during which bradykinesia and rigidity reappear, an absence of on periods and the development of involuntary dyskinesias<sup>2</sup>.

Although the diagnosis of PD relies on the clinical effects of dopamine deficiency, this disease is associated with other neurotransmitter deficits that are recognized to cause various motor and non-motor symptoms and signs. Some of these symptoms and signs — for example, hyposmia, rapid eye movement (REM) sleep behaviour disorder (RBD), depression and constipation — can precede the symptoms related to dopamine deficiency by several years<sup>3</sup>. Alternatively, these and other non-motor problems may arise later in the disease (FIG. 1). Global cognitive decline, in particular executive dysfunction and problems with working memory, has been also described in people at risk of developing PD<sup>4</sup>.

Although subtle cognitive deficits may be present at the diagnosis of PD, these become more significant in the later years of the disease, and they are often present in people with PD aged over 70 years old regardless of

the age of disease onset<sup>5</sup>. Indeed, with the progression of neurodegeneration and advancing disease, non-motor problems such as cognitive impairment, autonomic dysfunction and sleep disorders come to dominate the clinical picture and are the main determinants of quality of life and institutionalization<sup>6</sup> (FIG. 2). Indeed, recent evidence suggests that PD may have several endophenotypes, and some of these endophenotypes are dominated by non-motor symptoms<sup>7</sup>.

Two of the major therapeutic challenges for PD are the development of disease-modifying treatments to slow or prevent the progression of neurodegeneration and the development of effective symptomatic interventions for non-motor features. This Review summarizes the spectrum of non-motor problems in PD, addressing the pathological, pharmacological and clinical aspects of each non-motor feature, the model systems developed to study them, and the prospects of using such features to define a pre-diagnostic prodrome of PD. In discussing the potential modelling of non-motor features of PD, we recognize the limitations of existing toxin and genetic animal models in recapitulating the clinical and pathological characteristics of the disease, as well as its progressive nature — a feature specifically lacking in the toxin models. It is also important to distinguish animal models that are based on toxins, such as rotenone or 6-hydroxydopamine (6-OHDA), which do not act through mechanisms that reflect the complex pathogenic processes underlying PD, from those that are based on genetic forms of PD, most frequently  $\alpha$ -synuclein transgenic mice. The lessons from these mouse models are limited by the lack of comprehensive investigation of non-motor symptoms in any one study or any one non-motor symptom with different models,

<sup>1</sup>Department of Clinical Neurosciences, University College London (UCL) Institute of Neurology, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK.

<sup>2</sup>National Parkinson Foundation International Centre of Excellence, King's College Hospital, King's College London, Camberwell Road, London SE5 9RS, UK.

<sup>3</sup>Neurodegenerative Diseases Research Group, Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, Newcomen Street, London SE1 1UL, UK.

Correspondence to A.H.V.S. [a.schapira@ucl.ac.uk](mailto:a.schapira@ucl.ac.uk)

doi:10.1038/nrn.2017.62  
Published online 8 Jun 2017

**Table 1 | Overview of the brain regions and neurotransmitters implicated in the non-motor symptoms of Parkinson disease**

Non-motor symptom	Implicated brain region	Implicated neurotransmitter
Hyposmia	Olfactory bulb and amygdala	Substance P and acetylcholine
Impaired colour vision	Retina	Dopamine
Hallucinations	Occipital cortex	Dopamine
Pain	Basal ganglia, locus coeruleus, raphe nucleus, amygdala and thalamus	Dopamine, serotonin and noradrenaline
Anxiety	Basal ganglia	Dopamine and noradrenaline
Depression	Limbic and cortical areas	Dopamine and noradrenaline
Early cognitive dysfunction	Frontal cortex	Dopamine
Dementia	Temporal, parietal and occipital lobes	Acetylcholine
Sleep disturbance	Hypothalamus and reticular formation	Hypocretin, dopamine and serotonin
Bladder hyper-reflexia	Basal ganglia	Dopamine and acetylcholine

The associations in the table are simplified, and readers are referred to the text for details.

## Wearing off periods

Re-emergence of dopamine deficiency-related symptoms (for example, stiffness, slowness or tremor).

## Off periods

Similar to 'wearing off' but more severe in terms of symptom severity.

## On periods

Periods of effective dopamine replacement with restored motor function.

## Hyposmia

Reduction in the ability to detect odours.

## Rotenone

A mitochondrial complex I inhibitor and common pesticide.

## $\alpha$ -Synuclein

A protein that aggregates and forms the major constituent of Lewy bodies in neurons. Mutations in the gene encoding  $\alpha$ -synuclein and overexpression of this protein are causes of familial Parkinson disease.

## Anosmia

Loss of the sense of smell.

## Lewy bodies

Abnormal aggregates of proteinaceous material within neuronal cell bodies, the major constituent of which is  $\alpha$ -synuclein.

including different species and strains. No model type, toxin or genetic, has shown consistency in the evaluation of any specific non-motor feature. Furthermore, we also accept that the presence of motor symptoms may interfere with the ability to evaluate non-motor abnormalities such as anxiety, depression and cognition. Despite these caveats, the animal models described can provide some insight into the pathology and pharmacology of non-motor dysfunction in PD. The pharmacological basis of the non-motor features of PD is of relevance to the development of future therapies. Currently, dopaminergic treatments are the most widely used therapies, but they have no impact on those aspects of the disease that are related to other neurotransmitter deficits. This is reflected in the limited therapies available for non-motor deficits<sup>8</sup>.

## Sensory features


Sensory symptoms, and pain in particular, are common non-motor features of PD. Indeed, virtually all patients with PD experience at least one sensory symptom as part of their prodrome, and such symptoms increase in prevalence and severity with the progression of the disease.

**Olfactory deficits.** Hyposmia or anosmia develops in more than 90% of patients with PD, is usually bilateral and may precede the onset of the dopamine deficiency-related motor features<sup>9</sup>. Although hyposmia is not often reported by patients, the presence or progression of hyposmia could represent a biomarker for early pre-motor PD, particularly if it is combined with other early clinical, imaging and/or biochemical markers, such as reduced noradrenergic denervation of cardiac tissue and cognitive dysfunction<sup>10–14</sup>. The development of hyposmia and RBD (see below) may reflect the evolving distribution and spread of Lewy bodies in PD from the lower medulla, as described by Braak and colleagues<sup>15</sup> (FIG. 3). However, the presence of olfactory dysfunction in later stages of PD may also be linked to cholinergic denervation and the onset of cognitive deficits and dementia<sup>16,17</sup>.

Alterations in olfaction in PD seemingly owe to changes in central olfactory processing, as biopsy samples of the olfactory epithelium from individuals with the disease are normal<sup>18</sup>. Indeed, MRI studies revealed that, compared with healthy controls, individuals with PD showed varying degrees of decreased volume and sulcus depth in the olfactory bulb<sup>19</sup>. Moreover, Lewy bodies and Lewy neurites, as detected by  $\alpha$ -synuclein immunoreactivity, were found in the olfactory bulb, the olfactory cortex and other brain regions related to olfaction (including the amygdala) in patients with PD or incidental Lewy body disease (ILBD) but rarely in healthy controls<sup>20,21</sup>. Individuals with PD also showed a loss of mitral cells and substance P-containing cells in the olfactory bulb, and a reduction in the level of calcium-binding protein in this region, but dopaminergic or somatostatin-containing cells are rarely affected in either the olfactory bulb or associated nuclei<sup>22</sup>. Patients with PD also showed an increase in periglomerular dopaminergic neurons, although this finding was not specific to PD as it also occurred in Alzheimer disease (AD) and in frontotemporal dementia. The failure of olfactory deficits to respond to dopaminergic medications probably reflects the lack of involvement of dopaminergic systems in the olfactory defects<sup>23</sup>.

Some evidence exists for olfactory deficits in rodent models of PD, but this evidence has proved controversial. Mice and rats receiving intranasal or intraperitoneal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to model PD exhibited impaired olfaction and reductions in the levels of dopamine and noradrenaline in the olfactory bulb<sup>24,25</sup>. However, impaired olfaction following intranasal administration of MPTP may simply reflect damage to the olfactory epithelium<sup>26</sup>. No evidence exists to suggest that administration of MPTP causes olfactory changes in primates.

Mice overexpressing human wild-type  $\alpha$ -synuclein, a transgenic model of PD, have olfactory deficits: they show progressive losses in the abilities to detect and discriminate odours, which is associated with  $\alpha$ -synuclein accumulation in the olfactory bulb, although no evidence



**Figure 1 | Time courses of the onset of the motor and non-motor features of Parkinson disease. a** | A schematic representation of the potential timeline by which the non-motor features of Parkinson disease (PD) may manifest. Non-motor symptoms may develop insidiously in the prodromal phase several years before onset of motor features. The duration of this prodromal phase is variable, as is the sequence of the appearance of the non-motor symptoms. Clinical features of motor dysfunction are required for the diagnosis of PD, and early disease may be associated with the emergence of additional non-motor symptoms. Non-motor problems continue to develop throughout the course of the disease with cognitive and autonomic features becoming common in the later stages. The sequence, timing and development of the non-motor symptoms in PD can vary between patients. **b** | This part is a graphic depiction of the rates of development and progression of the motor and non-motor features of PD, and the decline in dopaminergic neuronal function. The rate of decline in dopaminergic function (caused by the dysfunction and death of dopaminergic neurons) in PD may be variable (as represented by the blue shaded region) and depends on genetic and/or non-genetic influences on aetiology. It is estimated that motor features appear when approximately 50–60% of dopaminergic neurons have been lost (represented by the dark blue shaded area)<sup>253</sup>. Diagnosis may be preceded by subtle emerging motor features not noticed by the patient. If left untreated, motor dysfunction progresses relatively rapidly after diagnosis. Symptomatic treatment with dopamine replacement drugs improves motor function, and the progression rate declines as a ceiling effect of disability is reached. Non-motor features may begin with an earlier pre-motor prodrome, progress more slowly but accumulate greater disability. The majority of non-motor features are not related to dopaminergic cell loss and so are unaffected by dopamine replacement therapy. RBD, REM sleep behaviour disorder.

#### Lewy neurites

Abnormal aggregates of proteinaceous material within axons, the major constituent of which is  $\alpha$ -synuclein.

**Incidental Lewy body disease (ILBD).** The presence on pathological examination of Lewy body deposition, but without symptoms of Parkinson disease during life.


**1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).** A mitochondrial complex I inhibitor that can cause dopaminergic neuron death and induce parkinsonism in humans.

exists for dopaminergic cell loss at least in the substantia nigra<sup>27–29</sup>. Mice expressing  $\alpha$ -synuclein–green fluorescent protein (GFP) also display olfactory dysfunction, as well as progressive motor impairment and the accumulation of  $\alpha$ -synuclein–GFP in the olfactory bulb<sup>30,31</sup>. These mice do not show increased sensitivity to olfactory neuronal loss following the administration of paraquat<sup>32</sup>. Furthermore, mice carrying the human  $\alpha$ -synuclein A53T mutation show progressive  $\alpha$ -synuclein accumulation in the olfactory bulb, marked loss of glutamatergic and calcium-binding protein immunoreactivity but no

change in the number of dopaminergic cells<sup>33</sup>. However, in this particular study, no assessment of olfaction was made.

Why rodents express some abnormalities in olfactory function and pathology in these toxin and genetic models is not clear, but these deficits may reflect the greater CNS representation of olfaction in these animals than in primates. Interestingly, the temporal expression pattern of  $\alpha$ -synuclein modulates olfactory neurogenesis in transgenic mice<sup>34</sup>. Therefore, overall, these findings are consistent with the concept that olfactory changes occur early

in the course of PD and can precede the onset of motor deficits that owe to dopaminergic cell loss, and that they may be linked to  $\alpha$ -synuclein-mediated pathology and to altered neurogenesis. Olfactory function has emerged as an important component of the PD clinical prodrome, but our ability to model its pathological basis has limited our understanding of its relationship to the progression of the disease.




**Figure 2 | Potential non-motor features in Parkinson disease.** The non-motor features of Parkinson disease reflect deficits in various functions of the CNS and autonomic nervous system. Multisystem involvement develops to varying levels of severity and in a variable sequence in different patients. Although some non-motor impairments precede motor abnormalities (for example, cardiac, bowel and olfactory deficits), most develop over time with progression of the underlying disease. Cognitive dysfunction usually appears late in the course of Parkinson disease, although visual hallucinations may appear earlier and are a risk factor for subsequent dementia. RBD, REM sleep behaviour disorder.

**Visual disturbances.** Visual disturbances in general are relatively common in PD with some studies reporting that up to 78% of patients are affected by such disturbances<sup>35,36</sup>, although another study reported that visual symptoms occurred in 22% of people with PD versus 4% of age-matched controls<sup>37</sup>. The incidence of visual hallucinations and diplopia (double vision) in PD increases with disease progression<sup>38</sup>. Impaired acuity does not improve with dopaminergic therapy, and indeed visual hallucinations may worsen, particularly with dopamine agonist treatment<sup>39</sup>. Some of the visual disturbances in PD, particularly hallucinations, have been linked to the presence of Lewy bodies in the occipital lobe and in retinal neurons, and to the loss of dopaminergic amacrine cells and the regulatory role of D1 dopamine receptors (D1Rs) and D2Rs in the eye<sup>40</sup>. Altered visual fields occur in primates following administration of the dopaminergic toxin MPTP and intraocular injection of the catecholaminergic toxin 6-OHDA, again suggesting some direct involvement of altered dopaminergic function in the eye<sup>41,42</sup>. There is also some evidence to suggest that thinning of the retinal nerve fibre layer occurs in patients with PD, as identified by ocular coherence tomography, but this finding is disputed<sup>43,44</sup>. Mutations in glucocerebrosidase (*GBA*) are numerically the most important risk factor for PD<sup>45</sup>, and retinal thinning has been described in carriers of these mutations with and without PD<sup>46</sup>. This finding suggests that retinal thinning may be used as part of a PD risk calculator for *GBA* mutation carriers. In PD patients with normal vision, electrical activity of the fovea, which is responsible for central acuity, is decreased, and retinal thinning is present<sup>47</sup>, which may reflect decreased innervation around the fovea and reduced retinal dopamine concentrations in these individuals.

Hallucinations, previously thought to be typical drug-related adverse effects in advancing PD, have now been reported to occur even in untreated PD in the prodromal phase<sup>48</sup>. The development of visual hallucinations is associated with cognitive impairment and dementia in PD, and such hallucinations may be a good predictor of cognitive decline in later disease<sup>49</sup>. Visual hallucinations in PD have been linked with perceptual, executive and sleep dysfunction and probably reflect the distribution of Lewy body pathology<sup>22,50</sup>. Treatment with dopaminergic therapies, especially dopamine agonists, is associated with an increased risk of visual hallucinations, implying that dopaminergic signalling is involved in their generation<sup>39</sup>.

**Pain and somatosensory disturbances.** Changes in sensory function and onset of pain are a common feature of PD affecting 30–85% of the patient population<sup>51–53</sup> and remain under-reported<sup>51,54–60</sup>. Pain in PD has various causes<sup>6,54–61</sup>. Several methods have been proposed to classify the complex pain syndrome of PD, and they mainly cover, or have been applied to, two broad categories of pain, nociceptive and neuropathic pain<sup>51,55</sup>. Pain also fluctuates with the motor state of the patient, often worsening during the off state (termed ‘off related pain’), whereas, in some patients, a central variant of pain is evident<sup>55–57,62,63</sup>.





**Figure 3 | Lewy bodies in Parkinson disease.** **a** | Lewy bodies are intraneuronal intracytoplasmic inclusions that are rich in  $\alpha$ -synuclein. In the left panel, a Lewy body is revealed by haematoxylin and eosin staining, whereas, in the right panel, this type of inclusion is revealed by  $\alpha$ -synuclein immunohistochemistry. Inclusions are also seen in axons and are referred to as Lewy neurites (not shown). **b** | The Braak hypothesis states that Lewy bodies first appear in the CNS in the lower medulla and olfactory nerves, and spread from the medulla up the brain stem to the midbrain where neurodegeneration first occurs in the dopaminergic neurons of the substantia nigra pars compacta (the darker the shaded area, the earlier it is affected). Subsequently, there is involvement of frontal and then occipital cortices<sup>254</sup>. BFB, basal forebrain; BN, brainstem nuclei; DMX, dorsal motor nucleus of the vagus nerve; MTC, mesiotemporal cortex; OB, olfactory bulb; SN, substantia nigra. Part **a** is courtesy of J. Holton, UCL Institute of Neurology, London, UK. Part **b** is adapted with permission from REF. 15, Elsevier, and from REF. 254, Macmillan Publishers Limited.

Various causes of sensory-related symptoms in PD have been identified, which can be largely divided according to whether they have a musculoskeletal origin (for example, causes that result in stiffness, dystonia or muscle cramps) or they have a central origin and are primarily related to the neurodegenerative process in PD<sup>6</sup>. Other sensory changes occur in PD, including peripheral paraesthesia, burning sensation and the so-called burning mouth syndrome, all of which can be recognized using the Chaudhuri–Schapira classification of pain in PD<sup>6</sup>.

The basal ganglia sustain sensory function through the modulation and integration of information from the substantia nigra, cortex, thalamus and many other nuclei. In PD, loss of dopaminergic input to the basal ganglia alters sensory perception and changes pain

thresholds<sup>64,65</sup>. However, dopamine can also modulate pain in regions outside of the basal ganglia, including the spinal cord, thalamus, periaqueductal grey and cingulate cortex<sup>66</sup>. Evidence exists indicating that dopaminergic function may modulate sensory perception: for instance, pain occurs more frequently in patients during off periods, and pain thresholds are raised by dopaminergic medication<sup>67</sup>. However, dopaminergic medication does not eliminate pain in PD, and therefore additional non-dopaminergic mechanisms must underlie this symptom. The ascending and descending pathways are involved in pain: for example, the spinothalamic tract sends collaterals to the locus coeruleus, raphe nuclei, amygdala and thalamus, and these areas receive inputs from higher centres to control the sensitivity and excitability of the somatosensory system<sup>68–70</sup>. The serotonergic raphe nuclei and the noradrenergic locus coeruleus are both affected by pathological change in PD, and both have a role in ‘gain setting’ for pain control<sup>71</sup>. The raphe nuclei send descending fibres to the dorsal horn of the spinal cord that modulate pain processing<sup>72</sup>, and the nociceptive neurons in lamina I of the dorsal horn show  $\alpha$ -synuclein immunoreactive inclusions in PD<sup>73</sup>. Peripheral deafferentation may also occur in PD, which may affect nociceptive input to the spinal cord<sup>74</sup>. Thus, multiple neurotransmitter pathways subserve the symptom of pain in PD, and it is challenging therefore to provide specific pain-relieving treatments.

In the clinical arena, classification of the type of pain in PD is essential for correct diagnosis and treatment. There are both dopaminergic and non-dopaminergic pain pathways, as well as neuropathic and nociceptive pain. Clinical classification is aided by the recent validation and description of the Kings Parkinson Pain Scale (KPPS), which is based on the Chaudhuri–Schapira classification of pain and classifies pain in PD to musculoskeletal, fluctuation related, central, nocturnal orofacial and peripheral pain<sup>75</sup>. The KPPS has aided the reporting of the first ever randomized placebo-controlled trial of an opiate (oxycodone combined with naloxone) to treat pain in PD (the PANDA study (NCT014391000))<sup>76</sup> and of a randomized trial with the rotigotine transdermal patch (the DOLORES study (NCT01744496))<sup>77</sup>.

The treatment of pain in PD is first directed to the relief of symptoms related to off periods and involves administration of dopaminergic medications; such agents may be combined with analgesics or pain-modulating drugs as required<sup>52</sup>. Painful dystonia may be relieved with botulinum injections in selected patients who do not respond to changes in their dopaminergic therapy<sup>78</sup>. Current evidence, therefore, allows clinical classification of pain using the KPPS and the initiation of individualized therapies. Fluctuation-related pain could be managed by strategies that use continuous drug delivery such as the rotigotine patch or other drugs given by infusion, whereas non-dopaminergic medication-responsive pain may require use of opiate or other analgesia, as suggested by the PANDA study<sup>79</sup>.

**Paraesthesia**  
Positive sensory phenomena  
(for example, pins and needles).

### Neuropsychiatric features

Neuropsychiatric features such as anxiety and depression occur in PD from the prodromal pre-motor phase to the late stages of the disease, and they fluctuate with the motor state; anxiety in particular is dominant during off periods. Overlap between anxiety and depression is also common, the anxious depressed phenotype and recognition is important for effective management.

**Anxiety.** Anxiety affects up to 60% of patients with PD and encompasses generalized anxiety (apprehension, fear and worry), panic attacks and social phobias, and it is commonly but not always accompanied by depression<sup>80,81</sup>. Anxiety is seen more commonly in females, patients with disease onset at a young age and patients with advanced disease<sup>82</sup>. Levels of anxiety increase with motor fluctuations, which are associated with periods of low dopamine levels, and with the onset of off periods or freezing<sup>83</sup>. Dopaminergic therapy and deep brain stimulation improve symptoms of depression, which may be secondary to improved motor function and could also indicate a dopaminergic component to anxiety<sup>81,84</sup>. Anxiety, often in association with depression, can occur before the onset of motor signs of PD, suggesting that this symptom may be related to pathology outside the nigrostriatal pathway<sup>85</sup>.

Positron emission tomography (PET) imaging using the catecholaminergic binding ligand <sup>11</sup>C-RTI-32 has revealed that, in PD patients with depression and anxiety but not PD patients without depression, there was a decrease in the binding of this ligand and that the level of binding was inversely correlated with the severity of anxiety but not depression<sup>86</sup>. This suggests that anxiety has a separate neurochemical basis to depression in PD patients with both. Clinical studies have also suggested the existence of several phenotypic variants of anxiety and depression in individuals with PD, ranging from those who exhibit both anxiety and depression to those with anxiety-alone or depression-alone subtypes<sup>82</sup>.

Bilateral 6-OHDA lesioning of the nigrostriatal pathway in rats leads to increased anxiety-like behaviour in the elevated plus maze and is associated with reductions in dopamine, noradrenaline and 5-hydroxytryptamine (5-HT; also known as serotonin) levels<sup>87</sup> in this task<sup>88</sup>. In genetic models of PD, parkin-null mice and vesicular monoamine transporter 2 (VMAT2)-deficient mice at 6 months show signs of anxiety-like behaviour in the elevated plus maze<sup>89,90</sup>. Overexpression of wild-type  $\alpha$ -synuclein in mice decreases anxiety-like behaviour in the elevated plus maze and the light–dark box paradigm, but this change in behaviour may reflect hyperactivity, as increased anxiety-like behaviour is observed in fear-conditioning tests in these mice<sup>28</sup>. In rats, subcutaneous infusion of paraquat and/or bilateral delivery of  $\alpha$ -synuclein into substantia nigra using a viral vector induced anxiety-like behaviour<sup>91</sup>. However, despite the behavioural changes observed in these models, little evidence exists to explain the pathological or biochemical basis for the expression of anxiety in people with PD.

**Depression.** Depression is common in patients with PD and considered clinically significant in 35% of the patient population<sup>92</sup>. In comparison with depression observed in people without PD, PD-related depression is generally milder, although it more frequently involves apathy and anhedonia.

Depression in PD may predate the onset of motor symptoms<sup>93</sup>. It has been correlated with disease duration, severity of motor symptoms, occurrence of motor complications or fluctuations and dosage of dopaminergic medication<sup>94</sup>. Moreover, cognitive decline and dementia, psychotic episodes, anxiety, sleep disturbance and autonomic symptoms have all been linked to an increased risk of depression in PD<sup>95</sup>. Thus, depression in PD is a complex phenomenon that may be a consequence of PD pathology, a reaction to the PD-associated disability, a separate phenomenon, or a combination of all three<sup>96</sup>. This possible complexity in the causation of PD probably accounts for the improvement of depression in only a proportion of PD patients with dopaminergic therapy.

As in endogenous depression, depression in PD is related to changes in dopaminergic, noradrenergic and serotonergic systems<sup>86</sup>. In addition, the loss of cortical cholinergic neurons may contribute to depression in PD. However, as the loss of this neuronal population also underlies the onset of dementia, it may be difficult to discriminate the clinical effects of such neurodegeneration in the early phase of dementia<sup>97</sup>.

Dopamine transporter availability in the striatum and limbic brain regions (the anterior cingulate cortex, amygdala and ventral striatum) is reduced in PD patients with depression compared with individuals with PD but not depression<sup>86,98</sup>. Furthermore, MRI has revealed that people with PD-related depression also show a loss of white matter in corticolimbic regions, which is a major site for the dopaminergic regulation of mood, motivation and reward<sup>99</sup>.

Serotonergic function is linked to depression in the general population, but there is mixed evidence for its involvement in depression in PD<sup>86</sup>. Degeneration of neurons in the raphe nuclei occurs in PD with a corresponding decrease in forebrain 5-HT innervation, as shown in imaging studies and post-mortem investigations. However, although there may be changes in 5-HT availability in the raphe nuclei and hypo-echogenicity on trans-cranial sonography, other functional imaging studies using PET failed to show any differences between the serotonergic systems in cases of PD with and without depression<sup>100</sup>. Cell loss in the dorsal raphe nuclei did not differ between PD patients with and without depression<sup>99</sup>. In addition, mixed evidence exists regarding whether selective 5-HT reuptake inhibitors are effective treatments for depression in PD<sup>101</sup>.

By contrast, there is stronger evidence for a change in noradrenergic function in depression in PD. Imaging studies have showed that PD patients with depression exhibit reductions in dopaminergic and noradrenergic innervation in the locus coeruleus, thalamus and limbic brain regions and increases in neuronal loss and gliosis in the locus coeruleus<sup>82,102,103</sup>.

#### Parkin

A protein that is involved in mitophagy.

#### Endogenous depression

Depressive symptoms that are not associated with triggers such as bereavement.

Interestingly, antidepressant drugs that affect noradrenaline reuptake, namely, tricyclic antidepressants like nortriptyline, may be more effective than other drugs in the treatment of PD-related depression<sup>104</sup>.

Increased depression-like behaviour has been observed using the forced swim and sucrose preference tests in 6-OHDA-lesioned and MPTP-treated rodents, and rotenone infusion into the substantia nigra in rats was associated with altered dopaminergic and serotonergic transmission<sup>89,105</sup>. VMAT2-deficient mice that showed a progressive depressive-like syndrome in the forced swim test also exhibited alterations in forebrain dopamine, noradrenaline and 5-HT levels<sup>91</sup>.

**Apathy and fatigue.** Apathy occurs in 60% of individuals with PD, and it is increasingly recognized as a distinct non-motor component of the disease<sup>106</sup>. Apathy may coexist with depression and dementia in PD but can also occur independently of both, and has been reported in cases of early-stage PD<sup>107,108</sup>. A report showed that, among individuals with PD, those with apathy had reductions in grey matter density in the cingulate gyrus and inferior frontal gyrus<sup>109</sup>, although another investigation did not find any frontotemporal atrophy in PD patients with apathy<sup>110</sup>. Alternatively, apathy in PD may involve ventral striatal and limbic brain areas, as a group of patients with PD developed apathy after deep brain stimulation in the subthalamic nucleus. Apathy in patients with PD has also been associated with atrophy of the left nucleus accumbens<sup>111</sup>. Finally, subtypes of apathy have been described and defined according to whether they are underpinned by a dopaminergic or a cholinergic dysfunction<sup>112</sup>.

MPTP-treated non-human primates also display apathetic behaviour. In such primates, apathetic behaviour correlated more strongly with loss of dopaminergic cells in the ventral tegmental area, which projects to the nucleus accumbens, and with expression levels of the dopamine transporter in the nucleus accumbens than with the degree of motor impairment. In patients with PD, apathy may improve with dopaminergic medication, but there has been little controlled evaluation of drug treatment<sup>105,106</sup>, although apathy occurring after DBS responded to treatment with a dopamine agonist (ropinirole)<sup>113</sup>.

Few clinical trials have focused on PD populations with apathy (as defined by the use of validated scales). One, 12-week placebo-controlled, double-blinded randomized study of pramipexole, a dopamine agonist, found that treatment with this agent at a dosage of up to 300 mg per day led to a 34.6% reduction in apathy scores at 12 weeks (by contrast, placebo reduced such scores by 3.2%)<sup>114</sup>. In addition, the role of the cholinergic system in apathy was translated to a 6-month multicentre, parallel, double-blind, placebo-controlled randomized controlled trial of rivastigmine (administered via a transdermal patch at 9.5 mg per day; CT00767091), which reported that this treatment led to a marked improvement in apathy<sup>115</sup>.

Fatigue in PD is characterized by a lack of energy, exhaustion and tiredness, is distinct from apathy, and affects approximately 50% of the patient population<sup>52</sup>.

Fatigue can be a consequence of motor dysfunction in PD or be directly related to the neuropathology, as it can be observed in treated patients with good motor function. The presence and severity of fatigue is not associated with the duration of PD or the severity of motor symptoms, and it can appear before motor signs are recognized. In some patients, but not all, fatigue may be associated with the presence of depression, nocturnal sleep disturbance and autonomic symptoms. There is no association between the presence of fatigue and the type, duration or dosage of anti-parkinsonian medication used for treatment, although it improves with a reduction in off periods<sup>116</sup>. Basal ganglia dysfunction has been implicated in fatigue because of their connections to the limbic system<sup>117</sup>. However, no differences in dopamine transporter expression in the striatum have been found between PD patients with and without fatigue<sup>118</sup>. By contrast, patients with PD and fatigue showed reduced 5-HT transporter levels in the caudate nucleus, putamen, ventral striatum, thalamus, cingulate and amygdala compared with PD patients without fatigue<sup>119</sup>.

**Cognitive deficits and dementia.** Cognitive decline and dementia are usually considered to be a component of late-stage PD or as a consequence of senescence; up to 83% of patients with PD may be affected by some level of cognitive dysfunction<sup>120</sup>. Individuals with a predominantly bradykinetic-rigid form of PD are more at risk of subsequently developing dementia than people who have a tremor-dominant form of the disease<sup>121</sup>. Late-onset dementia is characterized by visual spatial constructional deficits and recognition, semantic and episodic memory loss. These deficits do not have a basal ganglia origin but are associated with Lewy bodies in posterior cortical regions, notably, the parietal and temporal lobes. The density of cortical Lewy bodies and Lewy neurites seems to correlate with the severity of dementia<sup>122</sup>. Distinguishing individuals with PD with dementia from those patients with dementia with Lewy bodies (DLB) or AD is sometimes difficult because both clinical and pathological changes can overlap. Indeed, tau-positive, amyloid-positive and  $\alpha$ -synuclein-positive inclusions are present in all three conditions<sup>123</sup>.

Dementia in PD is accompanied by a substantial reduction in cortical cholinergic markers, explaining the limited clinical response to cholinesterase inhibitors that can be seen in some patients<sup>124</sup>. By contrast, dopaminergic drugs have little effect and can worsen psychosis and hallucinations associated with the dementia. However, the continual degeneration of brainstem nuclei as PD progresses may also be a contributory factor to cognitive decline in older patients. A greater loss of the dopamine transporter and dopaminergic terminals in the striatum and inferior frontal gyrus has been observed in PD with dementia than in PD without dementia<sup>125,126</sup>. There is also some evidence for a more severe loss of noradrenergic input from the locus coeruleus to cortical regions in cases of PD with dementia than in cases of PD but no dementia<sup>127</sup>.

Mild, usually clinically asymptomatic cognitive impairment is also a common but under-recognized component of early PD, and the main feature of this early cognitive syndrome is impairment in executive function<sup>128</sup>. Early cognitive impairment is considered to be a frontostriatal disorder that is dopamine dependent and, for which, some components (for example, executive function) may be improved by dopaminergic drugs<sup>129</sup>. Other features such as recognition memory and cognitive flexibility do not respond to such drugs, suggesting the involvement of different neurotransmitters<sup>128</sup>. Early cognitive impairment may also be influenced by polymorphisms affecting dopaminergic function. Polymorphisms determining high enzyme activity in the gene encoding catechol O-methyltransferase (COMT) are associated with less impairment and therefore suggest that early cognitive dysfunction is attributable to a state of relative hyperdopaminergic activity in the dorsolateral prefrontal cortex compared with that in the striatum<sup>130</sup>. Importantly, cortical dopamine levels rise in early PD to compensate for the loss of dopamine that occurs in the striatum<sup>131</sup>, and this compensation may adversely affect cognition, as there is an inverted U-shaped relationship between the dopamine concentration and cognition<sup>132</sup>. However, no change occurs in the density of D1Rs, which represent the dominant subtype of dopamine receptor that is present in cortical areas<sup>133</sup>. Too little or too much dopamine may therefore be detrimental, and this may explain why cognition fluctuates with disease progression and with dopaminergic medication<sup>134</sup>.

Cognitive deficits in PD have been extensively studied in rodents using lesions of the nigrostriatal pathway induced by 6-OHDA or MPTP<sup>28,135</sup>. Several tests on such rodents have shown that they exhibit impairments in cognition, but these deficits reflect the consequences of acute or severe lesions rather than the progressive pathology of PD, and so will not necessarily reflect the cognitive decline and dementia that are observed in humans with this disease. These observations of cognitive dysfunction are also limited by many tests being dependent on motor function and the consequent effect of an induced parkinsonian state on test performance. Changes in cognition have also been reported in ageing mice that overexpressed wild-type or mutant  $\alpha$ -synuclein<sup>136</sup>. In a conditional model, mice expressing high levels of human wild-type  $\alpha$ -synuclein in midbrain and forebrain regions showed cognitive impairment and developed mild nigral and hippocampal neuropathology<sup>137</sup>. However, in a different study, mice expressing human wild-type  $\alpha$ -synuclein and showing extensive cognitive deficits had no pathology in the hippocampus but exhibited cholinergic deficits in the cortex<sup>138</sup>. The cholinergic deficit may reflect early changes in brain regions outside the basal ganglia as this deficit preceded striatal dopamine loss. Early cognitive decline is also seen in MPTP-treated non-human primates, in which chronic low-dose treatment leads to alterations in executive function and attention<sup>139</sup>. These abnormalities are the same as those seen in patients in the early stages of PD, so this model seems to be promising for the testing of new drug entities for

cognitive dysfunction — for example, D1R agonists and  $\alpha 7$  subunit-containing nicotinic acetylcholine receptor agonists<sup>140,141</sup>, or other drugs that may target a specific pharmacological defect. However, MPTP is not associated with  $\alpha$ -synuclein pathology and so could not be used to test drugs designed to target  $\alpha$ -synuclein pathology and its role in cognitive decline.

**Psychosis.** Psychosis in PD typically occurs later in the course of the illness, and common symptoms include visual hallucinations and delusions, which are present in up to 40% of cases of PD<sup>100,142–144</sup>. Dopaminergic therapy with levodopa and dopamine agonists can induce psychosis, and such therapy was originally thought to explain its occurrence in PD.

Abnormal visual processing, sleep dysfunction, and pathological and neurochemical changes have all been linked to psychosis in PD<sup>144</sup>. Although MRI studies have shown little structural change in cortical regions in PD patients with psychosis compared with PD patients without psychosis, they have shown alterations in the processing of visual stimuli<sup>145</sup>. Decreases in retinal dopamine concentrations (see above) may also contribute to changes in visual perception and processing in PD<sup>146</sup>. During sleep, vivid dreams, nightmares and night terrors occur more frequently in those patients with psychoses, and these phenomena may have similar underlying mechanisms to daytime hallucinations<sup>147,148</sup>.

Classical antipsychotics such as dopamine antagonists and atypical 5-HT-based antipsychotics are used to control symptoms of psychosis, suggesting that dopamine and 5-HT may have a role in psychosis in PD. Among individuals with PD, forebrain 5-HT levels are lower in those with psychosis than in those without psychosis<sup>149</sup>. Acetylcholine may also contribute to psychosis, as cortical denervation in later stages of PD is related to susceptibility to psychosis in PD, as well as in AD<sup>150</sup>. Anticholinergic drug use can also cause the emergence of psychosis in PD possibly by further impairing already diminished cortical cholinergic transmission<sup>151</sup>. Hallucinations in PD are associated with the presence of Lewy bodies in the amygdala and the frontal, temporal, parietal and visual cortices, suggesting that pathological changes in PD may directly contribute to hallucinations<sup>152</sup>.

Few studies of experimental models of PD have investigated psychosis. In one study, a rating scale for psychosis-like behaviour in response to dopaminergic drugs was reported in MPTP-treated non-human primates<sup>153–155</sup>. Whether the behavioural changes observed reflected psychotic processes is a matter of conjecture, but the behaviours rated do respond to typical and atypical antipsychotic drug treatment.

### Sleep disorders

Disturbances in sleep and wakefulness affect most patients with PD, and their prevalence increases with the duration of disease<sup>156</sup>. Such disturbances take various forms. Daytime somnolence and ‘sleep attacks’ can be differentiated from nocturnal sleep disturbances.

Sleep attacks  
Sudden onset of sleep.



Night-time sleep disorders include insomnia, which can be disease-related or drug-related and involve sleep fragmentation and frequent, prolonged awakening, RBD, periodic limb movements, restless leg syndrome and akathisia<sup>157</sup>. The return of motor symptoms when drug effects wear off during the night, dyskinesia and/or dystonia related to drug action, nightmares, hallucinations and nocturia can all exacerbate sleep disturbances<sup>158</sup>.

Dopamine, noradrenaline and 5-HT are involved in the control of sleep, and all these transmitter systems are affected in PD<sup>159</sup>. Dopaminergic cells in the periaqueductal grey are activated during wakefulness in the rat, and lesions of this region increase sleep periods<sup>160</sup>. Excessive daytime sleepiness and sleep attacks may be worsened by some dopamine receptor agonist drugs, and sleep disorders, such as narcolepsy, may be treated using dopaminergic medications, suggesting a link to altered dopaminergic neuronal function<sup>161</sup>.

Dopaminergic neurons in the ventral tegmental area–substantia nigra receive inputs from hypothalamic hypocretin (also known as orexin) neurons, and form loops controlling arousal and wakefulness ascending through the thalamus and cortex and descending via the pedunculopontine nucleus and the reticular formation<sup>162</sup>. Hypocretin is almost undetectable in both PD and non-PD patients with narcolepsy, and decreases in the number of hypocretin neurons and in hypocretin levels in the cerebrospinal fluid and frontal cortex have been reported in PD<sup>163,164</sup>. Similarly, restless leg syndrome, periodic limb movements and akathisia seem to have a dopaminergic component, given that levodopa and dopamine receptor agonists can improve these symptoms<sup>81,165</sup>. However, what is not clear is whether the dopaminergic components are central, peripheral or both.

Insomnia in patients with PD also may be related to disease pathology but also to too little or too much dopaminergic therapy. MPTP-treated mice and monkeys have changes in sleep patterns and in REM sleep that can be manipulated by dopaminergic drugs, notably, D1R agonists<sup>166–169</sup>. By contrast, RBD seems to have a different origin as it can occur early in the course of the disease process, long before the onset of obvious motor signs<sup>170</sup>.

Braak and colleagues<sup>15</sup> have observed the distribution of Lewy bodies in non-PD post-mortem brains and suggested that early pathology begins in the lower brain stem and ascends to involve the midbrain and then the cortex. The olfactory nucleus may also be involved at the time of medullary Lewy body pathology, although neurodegeneration begins in the substantia nigra. Wild-type  $\alpha$ -synuclein overexpression leading to brain stem and cortical accumulation is associated with sleep disturbances in mice<sup>171</sup>. The concept of early brain stem involvement has been used to explain the early non-motor features of hyposmia and sleep disturbance in patients with PD<sup>172,173</sup>.

### Autonomic dysfunction

Autonomic dysfunction in PD is common and may precede motor features, but it becomes more prevalent as the disease progresses. Autonomic problems

encompass bladder, bowel and sexual dysfunction, as well as cardiovascular complications such as postural hypotension.

**Bladder dysfunction.** Urinary dysfunction in PD includes nocturia, and increased frequency and urgency of micturition, which are associated with detrusor hyper-reflexia. Micturition regulation is dependent on the autonomic arc of the sacral spinal cord segments, but it is tonically facilitated by the pontine micturition centre; the storage function is facilitated by the hypothalamus, cerebellum, frontal cortex and basal ganglia<sup>174–176</sup>. Bladder hyper-reflexia in PD is thought to be related to loss of the inhibitory role of the basal ganglia. Reduced dopaminergic function and globus pallidus activity can be seen in imaging studies in people with PD and bladder dysfunction compared with PD patients with normal bladder function<sup>177,178</sup>. More specifically, the D1R-mediated output from the basal ganglia has an inhibitory effect on micturition, but the D2R-mediated output is facilitatory<sup>179</sup>. Striatal dopamine transporter loss correlates with the severity of bladder symptoms, and caudate neurodegeneration with transporter loss may be a greater predictor for bladder symptoms than putamenal loss<sup>68</sup>. Bladder symptoms may improve in a minority of PD patients with dopaminergic therapy<sup>180</sup>. The dopaminergic effects are complex with postulated roles for D1Rs and D2Rs, dopamine autoreceptors and postsynaptic sites and central and peripheral dopamine receptor stimulation<sup>181</sup>. The complex pharmacological innervation presumably reflects the complexity of control of bladder function at multiple levels within the central and autonomic nervous systems.

The bladder itself is innervated by muscarinic and nicotinic cholinergic inputs and adrenergic and noradrenergic inputs<sup>182</sup>. No specific morphological, pathological or biochemical alterations have been found to occur in the bladder in patients with PD<sup>183</sup>. Most evidence for dopaminergic involvement in bladder function has arisen from experimental studies in animals. Unilateral lesions of the nigrostriatal pathway using 6-OHDA in the rat cause bladder hyper-reflexia, as does the administration of MPTP in non-human primate species<sup>184–187</sup>. Electrical stimulation of the substantia nigra and the direct injection of dopamine into the striatum can reverse these changes. Interestingly, D1R agonists improve bladder function, whereas D2R agonists either have no effect or make it worse<sup>188</sup>. More recently, stem cell placement in the median forebrain bundle of 6-OHDA-lesioned rats was shown to ameliorate bladder dysfunction<sup>189</sup>. Together, this evidence suggests a centrally mediated mechanism underlying hyper-reflexia in PD. There has been little activity in developing novel treatments specifically aimed at bladder dysfunction in PD, although adenosine A<sub>2A</sub> receptor antagonists have been suggested as potentially effective in PD, based on action at a supraspinal site in 6-OHDA-lesioned rats<sup>176</sup>.

**Gastrointestinal dysfunction.** Dysfunction occurs along the entire length of the gastrointestinal tract in PD and includes excessive salivation, dysphagia, impaired gastric

**Akathisia**  
Motor restlessness.

**Nocturia**  
The need to pass urine during the night.

**Micturition**  
The process of passing urine.

**Detrusor**  
A muscle that controls bladder function.

emptying, constipation and impaired defecation<sup>190</sup>. Small intestinal bacterial overgrowth may complicate 25–67% of cases with PD<sup>191</sup>. The cause of the gastrointestinal dysfunction is not well understood and may involve extrinsic and intrinsic pathological and biochemical changes. Multiple neurotransmitters and neuromodulators (for example, acetylcholine, 5-HT, dopamine, noradrenaline, vasoactive intestinal peptide (VIP) and nitric oxide) control bowel function, and it is unlikely that there is a single pharmacological basis that is responsible for all the gastrointestinal symptomatology that is observed in PD. The dorsal motor nucleus of the vagus is important in autonomic control of the bowel, and pathological change in this area occurs early in the development of PD. This may explain why gastrointestinal disturbances such as constipation may also occur earlier than alterations in motor function<sup>192</sup>.

Changes in the enteric nervous system (ENS) have also been reported in PD; for example, in one study, immunohistochemistry revealed a reduction in dopamine levels in the ENS, although there was no loss of tyrosine hydroxylase immunoreactivity, implying that no neurodegeneration had occurred<sup>193</sup>. A further study failed to show any neuronal loss in the myenteric plexus along the length of the gastrointestinal tract in control subjects, individuals with PD and cases of ILBD<sup>194</sup>. Also, no difference was observed between these groups in the relative abundance of tyrosine hydroxylase-containing, VIP-containing and nitric oxide-containing neurons. However, what is clear is the presence of Lewy bodies (and/or  $\alpha$ -synuclein inclusions and Lewy neurites) in PD at almost every level of the gastrointestinal tract<sup>195</sup>. There is virtually no colocalization of  $\alpha$ -synuclein with tyrosine hydroxylase, VIP or nitric oxide, suggesting that it is located in other neuronal types — perhaps cholinergic neurons.

The presence of  $\alpha$ -synuclein aggregations along the gastrointestinal tract has been proposed as a diagnostic tool allowing early detection of the disease process before the onset of motor symptoms. Biopsy samples have been taken at multiple levels from the salivary glands to the rectum to determine the validity of this approach<sup>196–201</sup>.  $\alpha$ -Synuclein aggregates in colonic tissue so far seem to be the more predictive of preclinical PD. However,  $\alpha$ -synuclein is abundantly expressed in all nerve plexuses of the ENS in normal individuals, and levels increase with age, so its pathological relevance needs to be carefully assessed before use as a predictive biomarker of PD<sup>202</sup>.

Abnormalities of gastrointestinal motility may be improved with both apomorphine and levodopa infusions<sup>81,203</sup>. The gastrointestinal effects of apomorphine are not prevented by the peripheral dopamine antagonist domperidone, suggesting that they have a central origin. There may also be a serotonergic component to impaired motility, and this is supported by enhanced gastrointestinal function following treatment with cisapride and related 5-HT<sub>4</sub> receptor agonists<sup>176</sup>.

Rodents treated with dopaminergic toxins or overexpressing wild-type or A53T mutant  $\alpha$ -synuclein can show slowed intestinal motility and constipation<sup>204–207</sup>.

In mice overexpressing human wild-type  $\alpha$ -synuclein, functional assessments demonstrated a reduction in faecal water content and faecal pellet output, and increased whole gut transit time, which is indicative of constipation<sup>208</sup>. Delayed gastric emptying was observed in 6-OHDA-lesioned rats, and this may reflect the delayed emptying that is observed in PD, which can affect levodopa absorption<sup>209</sup>. In unilateral 6-OHDA-lesioned rats, there was a marked loss of nitric oxide synthase-positive neurons and an increased number of VIP-positive cells in the myenteric plexus<sup>204</sup>. Moreover, in the colon of these animals, there was no change in choline acetyltransferase immunoreactivity, but there was selective loss in D2R density. By contrast, in the colon of MPTP-treated non-human primates, there was increased number of nitric synthase immunoreactive neurons, a decrease in tyrosine hydroxylase immunoreactivity and no change in cholinergic-immunoreactive or VIP-immunoreactive populations<sup>210</sup>. The differences in the rat and primate findings may lie in the focal degeneration of nigrostriatal neurons that is produced by intranigral 6-OHDA administration as opposed to the systemic administration of MPTP that could potentially also destroy peripheral dopaminergic cells. However, these results seem to contrast with the effects in man, as neither toxin would destroy neurons in the dorsal motor nucleus of the vagus.

**Cardiovascular features.** The heart is innervated by sympathetic (noradrenergic and adrenergic) and parasympathetic (cholinergic) autonomic fibres that control heart rate and contractility. Cardiac autonomic dysfunction may occur in up to 80% of patients with PD<sup>211</sup>. This dysfunction encompasses orthostatic hypotension and labile hypertension. Orthostatic hypotension is a marker of sympathetic dysfunction and is common in PD with a reported frequency of 30–58%<sup>212</sup>. Twenty-four hour blood pressure monitoring showed that alterations in blood pressure profile and supine hypertension often occur in PD, usually in patients who develop orthostatic hypotension<sup>213</sup>. Nocturnal (supine) hypertension in PD has been shown to be associated with target organ damage, as well as an increased risk of stroke and cardiovascular events<sup>214</sup>.

Motor response fluctuations in PD may also affect cardiovascular function, and off periods have been shown to be associated with hypertension, a higher resting heart rate and a greater orthostatic fall of blood pressure<sup>215</sup>. A study of non-motor features in untreated patients with PD and healthy controls reported that the former had a markedly raised heart rate, suggesting that this may serve as a marker of early PD<sup>216</sup>. Postprandial hypotension has also been documented in PD, which seems to worsen the motor state in PD after a carbohydrate load and may explain the absence of on periods that are often seen after a meal<sup>217</sup>. A retrospective analysis of cardiovascular stress testing in asymptomatic individuals showed that, during peak exercise, the maximum heart rate and the percentage of theoretical maximum heart rate were markedly lower in people that developed PD than in control subjects<sup>218</sup>.

Despite the clinical evidence for altered cardiovascular function in PD, there has been relatively little investigation of this change in function in experimental models of the disorder. An impaired baroreflex response occurs in mice overexpressing human wild-type  $\alpha$ -synuclein<sup>219</sup>. Moreover, mice expressing A53T mutant  $\alpha$ -synuclein show aberrant autonomic control of the heart, which is characterized by elevated resting heart rate and an impaired cardiovascular stress response, associated with reduced parasympathetic activity<sup>220</sup>. Systemic MPTP treatment of mice can lead to decreased cardiac uptake of <sup>125</sup>I-metaiodobenzylguanidine (MIBG), a physiological analogue of noradrenaline, decreased activity of cardiac noradrenaline transporter and reduced circulating and tissue levels of noradrenaline<sup>221–223</sup>. There may be recovery over time following toxin treatment, and myocardial nerve fibres are preserved despite changes in cardiac contractility<sup>224,225</sup>. By contrast, a single study of MPTP administration to non-human primates showed, if anything, an acute increase in 6-<sup>15</sup>F-fluorodopamine (<sup>15</sup>F-DA) on PET but no long-term changes in <sup>15</sup>F-DA imaging<sup>226</sup>. The differences in effects on cardiac innervation may be a

reflection of the much higher doses of MPTP used to treat mice versus primates and also to its relative selectivity for dopaminergic neurons, although acute MPTP treatment can exert a reversible ‘reserpine’-like effect that depletes all monoamines<sup>227</sup>.

The effects of MPTP on non-human primates is in marked contrast to the effects of peripheral 6-OHDA treatment of primates, which led to a marked reduction in <sup>15</sup>F-DA uptake, as would be expected from its known toxicity to noradrenergic innervation in peripheral tissues<sup>226</sup>. Indeed, in a subsequent study, intravenous administration of 6-OHDA to monkeys caused an almost total loss of <sup>11</sup>C-meta-hydroxyephedrine uptake, as judged by PET, followed by a partial progressive recovery but with decreased levels of circulating catecholamines<sup>228</sup>. This finding raises the issue of whether central dopamine loss has a role in peripheral cardiovascular change, which has been partially addressed in rats. Injection of 6-OHDA into the medial forebrain bundle decreased the nocturnal heart rate in rats, whereas injection into the ventral tegmental area altered circadian blood pressure regulation<sup>28,229</sup>. In a recent study, bilateral injection of 6-OHDA into rat substantia nigra lowered the mean arterial pressure, decreased heart rate and reduced sympathetic activity<sup>230</sup>. Overexpression of wild-type  $\alpha$ -synuclein in mice caused increased heart rate variability, whereas expression of A53T mutant  $\alpha$ -synuclein did not induce cardiac autonomic abnormalities despite inducing profound ENS changes<sup>28</sup>.

#### Box 1 | Non-motor features as biomarkers for Parkinson disease

Two areas of Parkinson disease (PD) research in non-motor features are of particular relevance to progress in this field: the development of biomarkers to identify pre-symptomatic PD<sup>243,244</sup> and to modify pathogenetic pathways that cause degeneration of dopaminergic and non-dopaminergic neurotransmitter systems<sup>245</sup>.


The diagnosis of PD remains dependent on the identification of motor signs that include bradykinesia and rigidity, with a unilateral resting tremor and a subsequent good response to levodopa. However, it has been recognized that these diagnostic features may be preceded by non-motor symptoms and signs<sup>246</sup>, which include hyposmia, sleep behaviour disorder, constipation and depression. Each of these symptoms may be present several years before the emergence of motor deficits. None of these symptoms is specific for PD, but the presence of combinations of these symptoms, and correlation with preclinical loss of dopamine observed by imaging, can improve sensitivity and specificity of the prediction for conversion from pre-symptomatic to symptomatic PD<sup>222,247</sup>.

A putative biomarker that changes in parallel to the progression of pathology and clinical features would be of particular value for testing treatments designed to slow the course of PD. The identification of genetic causes of PD and the recognition that they also cause non-motor features<sup>248</sup> have helped to identify predisposed individuals to participate in longitudinal studies to track the development of prodromal, preclinical symptoms and signs. However, only the cohorts of individuals with PD-associated mutations in leucine-rich repeat serine/threonine-protein kinase 2 (*LRRK2*) or glucocerebrosidase (*GBA*) are of sufficient size to perform such studies. It may also be possible to undertake ‘reverse genetics’ by metabolomic screening of defined population groups (for example, patients with *PINK1* or Parkinson disease protein 2 (*PARK2*) mutation-related PD) to identify a specific biochemical profile within this group and then seek this same profile to define those among an idiopathic group that might have an underlying mitochondrial defect. This approach is being used in the *GBA*-mutation population in which non-motor features of prodromal PD have been found in asymptomatic mutation carriers<sup>249</sup>. Follow-up of this cohort has shown progression of the non-motor, as well as motor, consequences of neurodegeneration evolving towards clinical PD<sup>250</sup>. It is hypothesized that those that convert to clinical PD will have exhibited a specific clinical and metabolic prodrome that may be used to identify those at risk of PD in the *GBA*-mutation carrier population. These individuals may then be the most appropriate population for stratification for disease-modifying treatments that may include small molecule chaperones<sup>251,252</sup>.

#### Perspectives

Until relatively recently, PD has primarily been considered a motor disorder, with its dominant clinical features the result of dopaminergic neuron degeneration. Although dopamine cell loss clearly has a major role in PD symptomatology and has been the basis for the development of dopamine-replacement symptomatic therapies, this focus on motor deficits has relegated non-motor problems to a secondary role. As a result, valuable insights on disease pathogenesis, clinical evolution and progression, and novel therapies have been missed or delayed. The emergence of non-motor abnormalities before motor deficits in PD has led to the use of these abnormalities to help to define an at-risk cohort of individuals (BOX 1). Probably the most useful of the prodromal non-motor features that may help to define a pre-motor phase are the loss of olfaction, the development of RBD, depression and constipation. However, before these features can be used to identify individuals at risk of PD, additional, more-specific clinical, genetic and/or biochemical markers will need to be identified.

The pattern and sequence of the emergence of non-motor symptoms support the concept of a prion-like conformational templating spread of  $\alpha$ -synuclein deposition from the gut through the autonomic plexi to the brain stem and beyond to the cortex<sup>231,232</sup>. Interneuronal spread of  $\alpha$ -synuclein has been confirmed in cell and animal models<sup>233–237</sup>. The observation that either injection of the proteasomal inhibitor PSI (proteasomal inhibitor-1;



**Figure 4 | Schema representing the hypothesis of pathology spread via the intestine in Parkinson disease.** The vagus nerve provides parasympathetic innervation to the intestine from the oesophagus to the colon via the oesophageal, coeliac and hypogastric plexi, which connect to the vagal nucleus in the medulla. It is hypothesized that factors that initiate  $\alpha$ -synuclein pathology enter the gut via the nose or mouth and that a prion-like spread of  $\alpha$ -synuclein misfolding may generate a cascade of pathology from the gut plexi to medulla and beyond, as proposed by Braak and colleagues<sup>73</sup>. Adapted with permission from REF. 232, Macmillan Publishers Limited.

N-[(phenylmethoxy)carbonyl]-L-isoleucyl-L-glutamyl-tert-butyl ester-N-[(1S)-1-formyl-3-methylbutyl]-L-alaninamide into the gastric wall or intragastric administration of the mitochondrial inhibitor rotenone may initiate  $\alpha$ -synuclein release in the gut and its transmission to the dorsal motor nucleus of the medulla and

substantia nigra of the midbrain supports two important concepts emerging in PD pathogenesis<sup>238,239</sup>. The first is that an intestinal trigger (for example, a toxin or gut microbiome) may initiate  $\alpha$ -synuclein release (and possibly oligomer formation) from autonomic nerves in the gut. The second is the potential for spread of  $\alpha$ -synuclein pathology through connected neuronal pathways to the brain. The pattern of spread from the gut to the brain may underlie the pre-motor features of autonomic gastrointestinal dysfunction in PD; for example, constipation, cardiac denervation as shown by MIBG and the development of RBD. It has been suggested that the neurodegenerative process spreads from the olfactory bulb, the autonomic gut plexi, the intermediolateral nucleus of the spinal cord and the dorsal motor nucleus of the vagus in a caudorostral direction to the brain, and also from the brainstem into the spinal cord<sup>73,240</sup> (FIG. 4). However, this pattern of spread may not apply to all patients with PD and 7–8% of patients have been reported with no  $\alpha$ -synuclein pathology in the dorsal motor nucleus<sup>241,242</sup>.

Thus, the focus on non-motor dysfunction in PD has informed and supported novel concepts of aetiology and pathogenesis. The early disturbance of olfaction, sleep and/or autonomic function implies neuronal dysfunction and is consistent with the sequence and pattern of the hypothesized spread of Lewy body  $\alpha$ -synuclein pathology. These early features have been proposed as indicators of prodromal, pre-motor PD.

## Conclusion

The increasing focus of research on non-motor aspects of PD has provided valuable insights into the diversity of the clinical, pathological and neurochemical features of this disorder. The symptoms and signs of non-motor symptoms and signs of PD are now the subject of validated clinical assessments that can detect their presence and follow their progression over time. The recognition that non-motor features may develop before motor signs is leading to their evaluation as possible biomarkers, although their detection is likely to be most effective in conjunction with imaging and biochemical parameters. Importantly, attention is now being focused on the treatment of non-motor features to improve patients' quality of life. As non-motor problems are a significant, if not even the predominant, determinant of PD patients' quality of life, it is essential that any intervention in PD pathogenesis to slow the disease targets not only dopaminergic signalling but also non-dopaminergic pathways.

- Berardelli, A. *et al.* EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. *Eur. J. Neurol.* **20**, 16–34 (2013). **This is a definitive and practical recommendation for the diagnostic process in PD.**
- Schapira, A. H., Emre, M., Jenner, P. & Poewe, W. Levodopa in the treatment of Parkinson's disease. *Eur. J. Neurol.* **16**, 982–989 (2009).
- Schapira, A. H. & Tolosa, E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. *Nat. Rev. Neurol.* **6**, 309–317 (2010).
- Chahine, L. M. *et al.* Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. *Mov. Disord.* **31**, 86–94 (2016).
- Kempster, P. A., O'Sullivan, S. S., Holton, J. L., Revesz, T. & Lees, A. J. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. *Brain* **133**, 1755–1762 (2010).
- Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol.* **5**, 235–245 (2006). **This article details the importance of comprehensive assessment of non-motor symptoms PD and management outline.**
- Marras, C. & Chaudhuri, K. R. Nonmotor features of Parkinson's disease subtypes. *Mov. Disord.* **31**, 1095–1102 (2016).
- Zesiewicz, T. A. *et al.* Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* **74**, 924–931 (2010). **This is the first consensus-based attempt for management of a range of relevant non-motor symptoms of PD.**
- Bohnen, N. I., Studenski, S. A., Constantine, G. M. & Moore, R. Y. Diagnostic performance of clinical motor and non-motor tests of Parkinson disease: a matched case-control study. *Eur. J. Neurol.* **15**, 685–691 (2008).



10. Ponsen, M. M. *et al.* Idiopathic hyposmia as a preclinical sign of Parkinson's disease. *Ann. Neurol.* **56**, 173–181 (2004).  
**This study highlights the importance of hyposmia as an often missed non-motor symptom in what we now know as prodromal PD.**
11. Iranzo, A. *et al.* Decreased striatal dopamine transporter uptake and substantia nigra hyperchogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. *Lancet Neurol.* **9**, 1070–1077 (2010).
12. Gaenslen, A. *et al.* Prodromal features for Parkinson's disease — baseline data from the TREND study. *Eur. J. Neurol.* **21**, 766–772 (2014).
13. Doty, R. L. Olfaction in Parkinson's disease and related disorders. *Neurobiol. Dis.* **46**, 527–552 (2012).
14. Baba, T. *et al.* Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. *Mov. Disord.* **26**, 621–628 (2011).
15. Braak, H. *et al.* Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging* **24**, 197–211 (2003).  
**This is a seminal paper on Braak staging in PD.**
16. Bohnen, N. I. *et al.* Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. *Brain* **133**, 1747–1754 (2010).
17. Bohnen, N. I. & Muller, M. L. *In vivo* neurochemical imaging of olfactory dysfunction in Parkinson's disease. *J. Neural Transm. (Vienna)* **120**, 571–576 (2013).
18. Witt, M. *et al.* Biopsies of olfactory epithelium in patients with Parkinson's disease. *Mov. Disord.* **24**, 906–914 (2009).
19. Wang, J. *et al.* Association of olfactory bulb volume and olfactory sulcus depth with olfactory function in patients with Parkinson disease. *AJNR Am. J. Neuroradiol.* **32**, 677–681 (2011).
20. Harding, A. J., Stimson, E., Henderson, J. M. & Halliday, G. M. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. *Brain* **125**, 2431–2445 (2002).
21. Silveira-Moriyama, L. *et al.* Regional differences in the severity of Lewy body pathology across the olfactory cortex. *Neurosci. Lett.* **453**, 77–80 (2009).
22. Ferrer, I. *et al.* Neurochemistry and the non-motor aspects of PD. *Neurobiol. Dis.* **46**, 508–526 (2012).
23. Mundinano, I. C. *et al.* Increased dopaminergic cells and protein aggregates in the olfactory bulb of patients with neurodegenerative disorders. *Acta Neuropathol.* **122**, 61–74 (2011).
24. Dluzen, D. E. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reduces norepinephrine concentrations in the olfactory bulbs of male mice. *Brain Res.* **586**, 144–147 (1992).
25. Prediger, R. D. *et al.* Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. *Neurotox. Res.* **17**, 114–129 (2010).
26. Kurtenbach, S., Wewering, S., Hatt, H., Neuhaus, E. M. & Lubbert, H. Olfaction in three genetic and two MPTP-induced Parkinson's disease mouse models. *PLoS ONE* **8**, e77509 (2013).
27. Magen, I. & Chesselet, M. F. Genetic mouse models of Parkinson's disease: the state of the art. *Prog. Brain Res.* **184**, 53–87 (2010).  
**This is a comprehensive review of genetic models in PD.**
28. McDowell, K. & Chesselet, M. F. Animal models of the non-motor features of Parkinson's disease. *Neurobiol. Dis.* **46**, 597–606 (2012).  
**This is one of the earliest papers on non-motor animal models of PD, which is still a key unmet need.**
29. Fleming, S. M. *et al.* Olfactory deficits in mice overexpressing human wildtype  $\alpha$ -synuclein. *Eur. J. Neurosci.* **28**, 247–256 (2008).
30. Hansen, C. *et al.* A novel  $\alpha$ -synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of  $\alpha$ -synuclein-GFP. *Neurobiol. Dis.* **56**, 145–155 (2013).
31. Petit, G. H. *et al.* Rasagiline ameliorates olfactory deficits in an  $\alpha$ -synuclein mouse model of Parkinson's disease. *PLoS ONE* **8**, e60691 (2013).
32. Nuber, S. *et al.* Environmental neurotoxic challenge of conditional  $\alpha$ -synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. *Acta Neuropathol.* **127**, 477–494 (2014).
33. Ubeda-Banon, I., Saiz-Sanchez, D., Rosa-Prieto, C. & Martínez-Marcos, A.  $\alpha$ -Synuclein in the olfactory system of a mouse model of Parkinson's disease: correlation with olfactory projections. *Brain Struct. Funct.* **217**, 447–458 (2012).
34. Schreglmann, S. R. *et al.* The temporal expression pattern of  $\alpha$ -synuclein modulates olfactory neurogenesis in transgenic mice. *PLoS ONE* **10**, e0126261 (2015).
35. Archibald, N. K., Clarke, M. P., Mosimann, U. P. & Burn, D. J. Visual symptoms in Parkinson's disease and Parkinson's disease dementia. *Mov. Disord.* **26**, 2387–2395 (2011).
36. Armstrong, R. A. Visual symptoms in Parkinson's disease. *Parkinsons Dis.* **2011**, 908306 (2011).
37. Chaudhuri, K. R. *et al.* International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. *Mov. Disord.* **21**, 916–923 (2006).
38. Nebe, A. & Ebersbach, G. Selective diplopia in Parkinson's disease: a special subtype of visual hallucination? *Mov. Disord.* **22**, 1175–1178 (2007).
39. Baker, W. L. *et al.* Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. *Parkinsonism Relat. Disord.* **15**, 287–294 (2009).
40. Bodis-Wollner, I. Retinopathy in Parkinson disease. *J. Neural Transm.* **116**, 1493–1501 (2009).
41. Ghilardi, M. F., Bodis-Wollner, I., Onofri, M. C., Marx, M. S. & Glover, A. A. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. *Brain* **111**, 131–149 (1988).
42. Ghilardi, M. F., Marx, M. S., Bodis-Wollner, I., Camras, C. B. & Glover, A. A. The effect of intraocular 6-hydroxydopamine on retinal processing of primates. *Ann. Neurol.* **25**, 357–364 (1989).
43. Archibald, N. K., Clarke, M. P., Mosimann, U. P. & Burn, D. J. Retinal thickness in Parkinson's disease. *Parkinsonism Relat. Disord.* **17**, 431–436 (2011).
44. Tsironi, E. E. *et al.* Perimetric and retinal nerve fiber layer findings in patients with Parkinson's disease. *BMC Ophthalmol.* **12**, 54 (2012).
45. Siebert, M., Sidransky, E. & Westbroek, W. Glucocerebrosidase is shaking up the synucleinopathies. *Brain* **137**, 1304–1322 (2014).
46. McNeill, A. *et al.* Retinal thinning in Gaucher disease patients and carriers: results of a pilot study. *Mol. Genet. Metab.* **109**, 221–223 (2013).
47. Moschos, M. M. *et al.* Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. *Eur. J. Ophthalmol.* **21**, 24–29 (2011).
48. Pagonabarraga, J. *et al.* Minor hallucinations occur in drug-naïve Parkinson's disease patients, even from the premotor phase. *Mov. Disord.* **31**, 45–52 (2016).
49. Archibald, N. K., Hutton, S. B., Clarke, M. P., Mosimann, U. P. & Burn, D. J. Visual exploration in Parkinson's disease and Parkinson's disease dementia. *Brain* **136**, 739–750 (2013).
50. Muller, A. J., Shine, J. M., Halliday, G. M. & Lewis, S. J. Visual hallucinations in Parkinson's disease: theoretical models. *Mov. Disord.* **29**, 1591–1598 (2014).
51. Negre-Pages, L., Regragui, W., Bouhassira, D., Grandjean, H. & Rascol, O. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. *Mov. Disord.* **23**, 1361–1369 (2008).  
**This is a controlled comprehensive study addressing the prevalence of various types of pain in PD.**
52. Del, S. F. & Albanese, A. Clinical management of pain and fatigue in Parkinson's disease. *Parkinsonism Relat. Disord.* **18** (Suppl. 1), S233–S236 (2012).
53. Beiske, A. G., Loge, J. H., Ronningen, A. & Svensson, E. Pain in Parkinson's disease: prevalence and characteristics. *Pain* **141**, 173–177 (2009).
54. Wasner, G. & Deuschl, G. Pains in Parkinson disease — many syndromes under one umbrella. *Nat. Rev. Neurol.* **8**, 284–294 (2012).
55. Lee, M. A., Walker, R. W., Hildreth, T. J. & Prentice, W. M. A survey of pain in idiopathic Parkinson's disease. *J. Pain Symptom Manage.* **32**, 462–469 (2006).
56. Sage, J. I. Pain in Parkinson's disease. *Curr. Treat. Opt. Neurol.* **6**, 191–200 (2004).
57. Ford, B. Pain in Parkinson's disease. *Mov. Disord.* **25** (Suppl. 1), S98–S103 (2010).
58. Politis, M. *et al.* Parkinson's disease symptoms: the patient's perspective. *Mov. Disord.* **25**, 1646–1651 (2010).
59. Chaudhuri, K. R. *et al.* The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. *Mov. Disord.* **25**, 704–709 (2010).  
**This is the first international prospective study to reveal the under-reporting of 30 common non-motor symptoms of PD.**
60. Defazio, G. *et al.* Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. *Arch. Neurol.* **65**, 1191–1194 (2008).
61. Defazio, G., Tinazzi, M. & Berardelli, A. How pain arises in Parkinson's disease? *Eur. J. Neurol.* **20**, 1517–1523 (2013).
62. Granovsky, Y. *et al.* Asymmetric pain processing in Parkinson's disease. *Eur. J. Neurol.* **20**, 1375–1382 (2013).
63. Lin, C. H., Wu, R. M., Chang, H. Y., Chiang, Y. T. & Lin, H. H. Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study. *Eur. J. Neurol.* **20**, 1398–1404 (2013).
64. Brefel-Courbon, C. *et al.* Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. *Mov. Disord.* **20**, 1557–1563 (2005).
65. Chudler, E. H., Foote, W. E. & Poletti, C. E. Responses of cat C1 spinal cord dorsal and ventral horn neurons to noxious and non-noxious stimulation of the head and face. *Brain Res.* **555**, 181–192 (1991).
66. Fil, A. *et al.* Pain in Parkinson disease: a review of the literature. *Parkinsonism Relat. Disord.* **19**, 285–294 (2013).
67. Gerdelat-Mas, A. *et al.* Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. *J. Neurol. Neurosurg. Psychiatry* **78**, 1140–1142 (2007).
68. Drake, D. F., Harkins, S. & Outubuddin, A. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. *NeuroRehabilitation* **20**, 335–341 (2005).
69. Grinberg, L. T., Rueb, U., Alho, A. T. & Heinsen, H. Brainstem pathology and non-motor symptoms in PD. *J. Neurol. Sci.* **289**, 81–88 (2010).
70. Juri, C., Rodriguez-Oroz, M. & Obeso, J. A. The pathophysiological basis of sensory disturbances in Parkinson's disease. *J. Neurol. Sci.* **289**, 60–65 (2010).
71. Scherder, E., Wolters, E., Polman, C., Sergeant, J. & Swaab, D. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. *Neurosci. Biobehav. Rev.* **29**, 1047–1056 (2005).
72. Willis, W. D. & Westlund, K. N. Neuroanatomy of the pain system and of the pathways that modulate pain. *J. Clin. Neurophysiol.* **14**, 2–31 (1997).
73. Braak, H., Sastre, M., Bohl, J. R., de Vos, R. A. & Del, T. K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. *Acta Neuropathol.* **113**, 421–429 (2007).  
**This is a key paper that changed our view of the pathophysiology of PD by introducing the concept of pre-nigral Lewy body deposition and the concept of sequential spreading of pathology.**
74. Nolano, M. *et al.* Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. *Brain* **131**, 1903–1911 (2008).
75. Chaudhuri, K. R. *et al.* King's Parkinson's disease pain scale, the first scale for pain in PD: an international validation. *Mov. Disord.* **30**, 1623–1631 (2015).
76. Trenkwalder, C. *et al.* Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. *Lancet Neurol.* **14**, 1161–1170 (2015).
77. Rascol, O. *et al.* A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on parkinson's disease-associated chronic pain. *J. Clin. Pharmacol.* **56**, 852–861 (2016).
78. Patel, N., Jankovic, J. & Hallett, M. Sensory aspects of movement disorders. *Lancet Neurol.* **13**, 100–112 (2014).
79. Schrag, A., Sauerbier, A. & Chaudhuri, K. R. New clinical trials for nonmotor manifestations of Parkinson's disease. *Mov. Disord.* **30**, 1490–1504 (2015).
80. Lin, C. H., Lin, J. W., Liu, Y. C., Chang, C. H. & Wu, R. M. Risk of Parkinson's disease following anxiety disorders: a nationwide population-based cohort study. *Eur. J. Neurol.* **22**, 1280–1287 (2015).

81. Chaudhuri, K. R. & Schapira, A. H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurol.* **8**, 464–474 (2009).
82. Brown, R. G. *et al.* Depression and anxiety related subtypes in Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* **82**, 803–809 (2011).
83. Storch, A. *et al.* Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. *Neurology* **80**, 800–809 (2013).  
**This is an important study relating off periods to non-motor symptoms, emphasizing that certain non-motor features are at least partially responsive to dopaminergic therapy.**
84. Ceravolo, R. *et al.* Mild affective symptoms in *de novo* Parkinson's disease patients: relationship with dopaminergic dysfunction. *Eur. J. Neurol.* **20**, 480–485 (2013).
85. Clark, A. J., Ritz, B., Prescott, E. & Rod, N. H. Psychosocial risk factors, pre-motor symptoms and first-time hospitalization with Parkinson's disease: a prospective cohort study. *Eur. J. Neurol.* **20**, 1113–1120 (2013).
86. Remy, P., Doder, M., Lees, A., Turjanski, N. & Brooks, D. Depression in Parkinson's disease: loss of dopamine and noradrenergic innervation in the limbic system. *Brain* **128**, 1314–1322 (2005).
87. Tadaiesky, M. T. *et al.* Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. *Neuroscience* **156**, 850–840 (2008).
88. Vuckovic, M. G. *et al.* Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. *Neurobiol. Dis.* **32**, 319–327 (2008).
89. Taylor, T. N. *et al.* Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. *J. Neurosci.* **29**, 8103–8113 (2009).
90. Zhu, X. R. *et al.* Non-motor behavioural impairments in parkin-deficient mice. *Eur. J. Neurosci.* **26**, 1902–1911 (2007).
91. Campos, F. L. *et al.* Rodent models of Parkinson's disease: beyond the motor symptomatology. *Front. Behav. Neurosci.* **7**, 175 (2013).
92. Reijnders, J. S., Ehrt, U., Weber, W. E., Aarsland, D. & Leentjens, A. F. A systematic review of prevalence studies of depression in Parkinson's disease. *Mov. Disord.* **23**, 183–189 (2008).
93. Shiba, M. *et al.* Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. *Mov. Disord.* **15**, 669–677 (2000).
94. Dissanayake, N. N. *et al.* Factors associated with depression in Parkinson's disease. *J. Affect. Disord.* **132**, 82–88 (2011).
95. Santangelo, G. *et al.* Subthreshold depression and subjective cognitive complaints in Parkinson's disease. *Eur. J. Neurol.* **21**, 541–544 (2014).
96. Even, C. & Weintraub, D. Is depression in Parkinson's disease (PD) a specific entity? *J. Affect. Disord.* **139**, 103–112 (2012).
97. Di, G. D. *et al.* Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. *Eur. J. Nucl. Med. Mol. Imaging* **39**, 1937–1948 (2012).
98. Vriend, C. *et al.* Depressive symptoms in Parkinson's disease are related to reduced [<sup>123</sup>I]FP-CIT binding in the caudate nucleus. *J. Neurol. Neurosurg. Psychiatry* **85**, 159–164 (2014).
99. Kostic, V. S. *et al.* Regional patterns of brain tissue loss associated with depression in Parkinson disease. *Neurology* **75**, 857–863 (2010).
100. Gallagher, D. A. & Schrag, A. Psychosis, apathy, depression and anxiety in Parkinson's disease. *Neurobiol. Dis.* **46**, 581–589 (2012).  
**This is a helpful review of the non-motor symptoms of PD.**
101. Seppi, K. *et al.* The Movement Disorder Society Evidence-Based Medicine Review update: treatments for the non-motor symptoms of Parkinson's disease. *Mov. Disord.* **26** (Suppl. 3), S42–S80 (2011).
102. Burn, D. J. *et al.* Parkinson's disease motor subtypes and mood. *Mov. Disord.* **27**, 379–386 (2012).
103. Frisina, P. G., Haroutunian, V. & Libow, L. S. The neuropathological basis for depression in Parkinson's disease. *Parkinsonism Relat. Disord.* **15**, 144–148 (2009).
104. Menza, M. *et al.* A controlled trial of antidepressants in patients with Parkinson disease and depression. *Neurology* **72**, 886–892 (2009).
105. Czernecki, V. *et al.* Motivation, reward, and Parkinson's disease: influence of dopaminergic. *Neuropsychologia* **40**, 2257–2267 (2002).
106. Marin, R. S., Fogel, B. S., Hawkins, J., Duffy, J. & Krupp, B. Apathy: a treatable syndrome. *J. Neuropsychiatry Clin. Neurosci.* **7**, 23–30 (1995).
107. Pedersen, K. F. *et al.* Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. *J. Neurol.* **257**, 217–223 (2010).
108. Santangelo, G. *et al.* Apathy in untreated. *de novo* patients with Parkinson's disease: validation study of Apathy Evaluation Scale. *J. Neurol.* **261**, 2319–2328 (2014).
109. Dujardin, K. *et al.* Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. *Mov. Disord.* **29**, 1796–1801 (2014).
110. Isella, V. *et al.* Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. *Mov. Disord.* **17**, 366–371 (2002).
111. Carriere, N. *et al.* Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: a magnetic resonance imaging shape analysis. *Mov. Disord.* **29**, 897–903 (2014).
112. Pagonabarraga, J. *et al.* Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. *Lancet Neurol.* **14**, 518–531 (2015).
113. Czernecki, V. *et al.* Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. *Mov. Disord.* **23**, 964–969 (2008).
114. Thobois, S. *et al.* Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. *Brain* **136**, 1568–1577 (2013).
115. Devos, D. *et al.* Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. *J. Neurol. Neurosurg. Psychiatry* **85**, 668–674 (2014).
116. Hagell, P. & Brundin, L. Towards an understanding of fatigue in Parkinson disease. *J. Neurol. Neurosurg. Psychiatry* **80**, 489–492 (2009).
117. Chaudhuri, A. & Behan, P. O. Fatigue in neurological disorders. *Lancet* **363**, 978–988 (2004).
118. Schifitto, G. *et al.* Fatigue in levodopa-naïve subjects with Parkinson disease. *Neurology* **71**, 481–485 (2008).
119. Pavese, N., Metta, V., Bose, S. K., Chaudhuri, K. R. & Brooks, D. J. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. *Brain* **133**, 3434–3443 (2010).  
**This study provides an in vivo demonstration of abnormal central pharmacology in fatigue in PD.**
120. Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. *Mov. Disord.* **23**, 837–844 (2008).
121. Alves, G., Larsen, J. P., Emre, M., Wentzel-Larsen, T. & Aarsland, D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. *Mov. Disord.* **21**, 1123–1130 (2006).
122. Churchyard, A. & Lees, A. J. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. *Neurology* **49**, 1570–1576 (1997).
123. Halliday, G. M., Leverenz, J. B., Schneider, J. S. & Adler, C. H. The neurobiological basis of cognitive impairment in Parkinson's disease. *Mov. Disord.* **29**, 634–650 (2014).
124. Emre, M. *et al.* Cognitive impairment and dementia in Parkinson's disease: practical issues and management. *Mov. Disord.* **29**, 663 (2014).
125. Lewis, S. J., Dove, A., Robbins, T. W., Barker, R. A. & Owen, A. M. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. *J. Neurosci.* **23**, 6351–6356 (2003).
126. Rinne, J. O. *et al.* Cognitive impairment and the brain dopaminergic system in Parkinson disease: [<sup>18</sup>F] fluorodopa positron emission tomographic study. *Arch. Neurol.* **57**, 470–475 (2000).
127. Chan-Palay, V. & Asan, E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. *J. Comp. Neurol.* **287**, 373–392 (1989).
128. Kehagia, A. A., Barker, R. A. & Robbins, T. W. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. *Neurodegener. Dis.* **11**, 79–92 (2013).
129. Mattay, V. S. *et al.* Dopaminergic modulation of cortical function in patients with Parkinson's disease. *Ann. Neurol.* **51**, 156–164 (2002).
130. Foltynie, T. *et al.* Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. *Mov. Disord.* **19**, 885–891 (2004).
131. Rakshi, J. S. *et al.* Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [<sup>18</sup>F]dopa-PET study. *Brain* **122**, 1637–1650 (1999).
132. Robbins, T. W. Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications. *Phil. Trans. R. Soc. B* **362**, 917–932 (2007).
133. Cropley, V. L. *et al.* Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [<sup>11</sup>C] NNC 112 and [<sup>18</sup>F]FDOPA. *Psychiatry Res.* **163**, 171–182 (2008).
134. Janvin, C. C., Larsen, J. P., Aarsland, D. & Hugdahl, K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. *Mov. Disord.* **21**, 1343–1349 (2006).
135. Lindgren, H. S. & Dunnett, S. B. Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models? *Eur. J. Neurosci.* **35**, 1894–1907 (2012).
136. Masliah, E. *et al.* Passive immunization reduces behavioral and neuropathological deficits in an  $\alpha$ -synuclein transgenic model of Lewy body disease. *PLoS ONE* **6**, e19338 (2011).
137. Nuber, S. *et al.* Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. *J. Neurosci.* **28**, 2471–2484 (2008).
138. Magen, I. *et al.* Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. *Eur. J. Neurosci.* **35**, 870–882 (2012).
139. Decamp, E. & Schneider, J. S. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. *Eur. J. Neurosci.* **20**, 1371–1378 (2004).
140. Schneider, J. S., Sun, Z. Q. & Roeltgen, D. P. Effects of dihydroxide, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. *Brain Res.* **663**, 140–144 (1994).
141. Schneider, J. S., Tinker, J. P., Menzaghi, F. & Lloyd, G. K. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. *J. Pharmacol. Exp. Ther.* **306**, 401–406 (2003).
142. Diederich, N. J., Goetz, C. G. & Stebbins, G. T. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. *Mov. Disord.* **20**, 130–140 (2005).
143. Papapetropoulos, S. & Mash, D. C. Psychotic symptoms in Parkinson's disease. From description to etiology. *J. Neurol.* **252**, 753–764 (2005).
144. Zahodne, L. B. & Fernandez, H. H. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. *Drugs Aging* **25**, 665–682 (2008).
145. Stebbins, G. T. *et al.* Altered cortical visual processing in PD with hallucinations: an fMRI study. *Neurology* **63**, 1409–1416 (2004).
146. Bodis-Wollner, I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. *Trends Neurosci.* **13**, 296–302 (1990).
147. Moskovitz, C., Moses, H. III & Klawans, H. L. Levodopa-induced psychosis: a kindling phenomenon. *Am. J. Psychiatry* **135**, 669–675 (1978).
148. Pappert, E. J., Goetz, C. G., Niederman, F. G., Raman, R. & Leurgans, S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. *Mov. Disord.* **14**, 117–121 (1999).
149. Birkmayer, W. & Riederer, P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). *J. Neural Transm.* **37**, 175–182 (1975).
150. Kuhl, D. E. *et al.* In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. *Ann. Neurol.* **40**, 399–410 (1996).
151. van, H. G., Berger, H. J. & Horstink, M. W. Short-term memory in Parkinson's disease after withdrawal of long-term anticholinergic therapy. *Clin. Neuropharmacol.* **16**, 438–443 (1993).

152. Papapetropoulos, S., McCorquodale, D. S., Gonzalez, J., Jean-Gilles, L. & Mash, D. C. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. *Parkinsonism Relat. Disord.* **12**, 253–256 (2006).
153. Fox, S. H. *et al.* Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. *Can. J. Neurol. Sci.* **37**, 86–95 (2010).
154. Fox, S. H. *et al.* Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson's disease. *Arch. Neurol.* **63**, 1343–1344 (2006).
155. Visanji, N. P. *et al.* Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. *Mov. Disord.* **21**, 1879–1891 (2006).
156. Olanow, C. W., Schapira, A. H. & Roth, T. Waking up to sleep episodes in Parkinson's disease. *Mov. Disord.* **15**, 212–215 (2000).
157. Louter, M. *et al.* Sleep matters in Parkinson's disease: use of a priority list to assess the presence of sleep disturbances. *Eur. J. Neurol.* **20**, 259–265 (2013).
158. Klingelhofer, L., Sokolov, E. & Chaudhuri, K. R. Therapeutic options for nocturnal problems in Parkinson's disease and atypical parkinsonian disorders. *J. Neural Transm. (Vienna)* **121** (Suppl. 1), S25–S31 (2014).
159. Garcia-Borreguero, D., Larrosa, O. & Bravo, M. Parkinson's disease and sleep. *Sleep Med. Rev.* **7**, 115–129 (2003).
160. Rye, D. B. & Jankovic, J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. *Neurology* **58**, 341–346 (2002).
161. Schapira, A. H. Sleep attacks (sleep episodes) with pergolide. *Lancet* **355**, 1332–1333 (2000).
162. Zeitzer, J. M. Control of sleep and wakefulness in health and disease. *Prog. Mol. Biol. Transl. Sci.* **119**, 137–154 (2013).
163. Fronczek, R. *et al.* Hypocretin (orexin) loss in Parkinson's disease. *Brain* **130**, 1577–1585 (2007).
164. Thannickal, T. C., Lai, Y. Y. & Siegel, J. M. Hypocretin (orexin) cell loss in Parkinson's disease. *Brain* **130**, 1586–1595 (2007).
165. Schapira, A. H. Restless legs syndrome: an update on treatment options. *Drugs* **64**, 149–158 (2004).
166. Barraud, Q. *et al.* Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. *Exp. Neurol.* **219**, 574–582 (2009).
167. Hyacinthe, C., Barraud, Q., Tison, F., Bezard, E. & Ghorayeb, I. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. *Neurobiol. Dis.* **63**, 20–24 (2014).
168. Lima, M. M., Andersen, M. L., Reksidler, A. B., Vital, M. A. & Tufik, S. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. *PLoS ONE* **2**, e513 (2007).
169. Verhave, P. S. *et al.* REM sleep behavior disorder in the marmoset MPTP model of early Parkinson disease. *Sleep* **34**, 1119–1125 (2011).
170. Postuma, R. B. *et al.* Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. *Neurology* **84**, 1104–1113 (2015).
171. McDowell, K. A., Shin, D., Roos, K. P. & Chesselet, M. F. Sleep dysfunction and EEG alterations in mice overexpressing  $\alpha$ -synuclein. *J. Parkinsons Dis.* **4**, 531–539 (2014).
172. Boeve, B. F. *et al.* Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. *Brain* **130**, 2770–2788 (2007).
173. Ferrer, I., Martinez, A., Blanco, R., Dalfo, E. & Carmona, M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. *J. Neural Transm.* **118**, 821–839 (2011).
174. Blackett, H., Walker, R. & Wood, B. Urinary dysfunction in Parkinson's disease: a review. *Parkinsonism Relat. Disord.* **15**, 81–87 (2009).
175. Sakakibara, R. *et al.* Pathophysiology of bladder dysfunction in Parkinson's disease. *Neurobiol. Dis.* **46**, 565–571 (2012).
176. Sakakibara, R., Uchiyama, T., Yamanishi, T., Shirai, K. & Hattori, T. Bladder and bowel dysfunction in Parkinson's disease. *J. Neural Transm.* **115**, 443–460 (2008).
177. Sakakibara, R. *et al.* SPECT imaging of the dopamine transporter with [ $^{123}$ I]- $\beta$ -CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. *J. Neurol. Sci.* **187**, 55–59 (2001).
178. Winge, K., Friberg, L., Werdelin, L., Nielsen, K. K. & Stimpel, H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. *Eur. J. Neurol.* **12**, 842–850 (2005).
179. Seki, S. *et al.* Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. *Neurobiol. Urodyn.* **20**, 105–113 (2001).
180. Yoshimura, N., Miyazato, M., Kitta, T. & Yoshikawa, S. Central nervous targets for the treatment of bladder dysfunction. *Neurobiol. Urodyn.* **33**, 59–66 (2014).
181. Seth, J. H., Panicker, J. N. & Fowler, C. J. The neurological organization of micturition. *Handb. Clin. Neurol.* **117**, 111–117 (2013).
182. de Groat, W. C. Integrative control of the lower urinary tract: preclinical perspective. *Br. J. Pharmacol.* **147** (Suppl. 2), S25–S40 (2006).
183. McDonald, Winge, C. K. & Burn, D. J. Lower urinary tract symptoms in Parkinson's disease: prevalence, aetiology and management. *Parkinsonism Relat. Disord.* **35**, 8–16 (2017).
184. Albanese, A., Jenner, P., Marsden, C. D. & Stephenson, J. D. Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Neurosci. Lett.* **87**, 46–50 (1988).
185. Soler, R., Fullhase, C., Santos, C. & Andersson, K. E. Development of bladder dysfunction in a rat model of dopaminergic brain lesion. *Neurobiol. Urodyn.* **30**, 188–193 (2011).
186. Yoshimura, N., Kuno, S., Chancellor, M. B., de Groat, W. C. & Seki, S. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. *Br. J. Pharmacol.* **139**, 1425–1432 (2003).
187. Yoshimura, N., Mizuta, E., Kuno, S., Sasa, M. & Yoshida, O. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *Neuropharmacology* **32**, 315–321 (1993).
188. Yoshimura, N., Mizuta, E., Yoshida, O. & Kuno, S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. *J. Pharmacol. Exp. Ther.* **286**, 228–233 (1998).
189. Soler, R. *et al.* Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. *J. Urol.* **187**, 1491–1497 (2012).
190. Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E. & Pfeiffer, R. F. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol.* **14**, 625–639 (2015).
191. Tan, A. H. *et al.* Small intestinal bacterial overgrowth in Parkinson's disease. *Parkinsonism Relat. Disord.* **20**, 535–540 (2014).
192. Abbott, R. D. *et al.* Frequency of bowel movements and the future risk of Parkinson's disease. *Neurology* **57**, 456–462 (2001).
193. Singaram, C. *et al.* Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. *Lancet* **346**, 861–864 (1995).
194. Annerino, D. M. *et al.* Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. *Acta Neuropathol.* **124**, 665–680 (2012).
195. Gelpi, E. *et al.* Multiple organ involvement by  $\alpha$ -synuclein pathology in Lewy body disorders. *Mov. Disord.* **29**, 1010–1018 (2014).
196. Cersosimo, M. G. *et al.*  $\alpha$ -Synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients. *Mov. Disord.* **26**, 188–190 (2011).
197. Sanchez-Ferro, A. *et al.* In vivo gastric detection of  $\alpha$ -synuclein inclusions in Parkinson's disease. *Mov. Disord.* **30**, 517–524 (2015).
198. Poulet, H. *et al.* A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. *Neurogastroenterol. Motil.* **24**, e202 (2012).
199. Poulet, H. *et al.* A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson's disease. *Neurobiol. Dis.* **45**, 305–309 (2012).
200. Poulet, H., Lebouvier, T., Coron, E., Neunlist, M. & Derkinderen, P. Lewy pathology in gastric and duodenal biopsies in Parkinson's Disease. *Mov. Disord.* **27**, 708 (2012).
201. Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S. & Kordower, J. H. Is  $\alpha$ -synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. *Mov. Disord.* **27**, 716–719 (2012).  
**This is an interesting study proposing that  $\alpha$ -synuclein pathology appears in the colon years before the diagnosis of PD.**
202. Böttner, M. *et al.* Expression pattern and localization of  $\alpha$ -synuclein in the human enteric nervous system. *Neurobiol. Dis.* **48**, 474–480 (2012).
203. Honig, H. *et al.* Intrajeunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. *Mov. Disord.* **24**, 1468–1474 (2009).  
**This is one of the first studies to address the effect of continuous drug delivery of intrajeunal levodopa and its effect on non-motor symptoms as a whole.**
204. Colucci, M. *et al.* Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. *Auton. Neurosci.* **169**, 77–86 (2012).
205. Drolet, R. E., Cannon, J. R., Montero, L. & Greenamyre, J. T. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. *Neurobiol. Dis.* **36**, 96–102 (2009).  
**This is a seminal paper showing that complex I inhibition causes  $\alpha$ -synuclein pathology in the autonomic system.**
206. Noorian, A. R. *et al.*  $\alpha$ -Synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. *Neurobiol. Dis.* **48**, 9–19 (2012).
207. Wang, L. *et al.* Mice overexpressing wild-type human  $\alpha$ -synuclein display alterations in colonic myenteric ganglia and defecation. *Neurogastroenterol. Motil.* **24**, e425–e436 (2012).
208. Hallett, P. J., McLean, J. R., Kartunen, A., Langston, J. W. & Isacson, O.  $\alpha$ -Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. *Neurobiol. Dis.* **47**, 258–267 (2012).
209. Karasawa, H. *et al.* New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease. *Neurogastroenterol. Motil.* **26**, 1771–1782 (2014).
210. Chaumette, T. *et al.* Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. *Neurogastroenterol. Motil.* **21**, 215–222 (2009).
211. Goldstein, D. S. *et al.* Cardiac sympathetic denervation in Parkinson disease. *Ann. Intern. Med.* **133**, 338–347 (2000).
212. Goldstein, D. S. Orthostatic hypotension as an early finding in Parkinson's disease. *Clin. Auton. Res.* **16**, 46–54 (2006).
213. Schmidt, C. *et al.* Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. *Mov. Disord.* **24**, 2136–2142 (2009).
214. Fanciulli, A. *et al.* The potential prognostic role of cardiovascular autonomic failure in  $\alpha$ -synucleinopathies. *Eur. J. Neurol.* **20**, 231–235 (2013).
215. Goetz, C. G., Litke, W. & Tanner, C. M. Autonomic dysfunction in Parkinson's disease. *Neurology* **36**, 73–75 (1986).
216. Pilleri, M. *et al.* Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. *Parkinsonism Relat. Disord.* **20**, 217–221 (2014).
217. Chaudhuri, K. R. *et al.* Postprandial hypotension and parkinsonian state in Parkinson's disease. *Mov. Disord.* **12**, 877–884 (1997).
218. Palma, J. A. *et al.* Is cardiac function impaired in premotor Parkinson's disease? A retrospective cohort study. *Mov. Disord.* **28**, 591–596 (2013).
219. Fleming, S. M. *et al.* Impaired baroreflex function in mice overexpressing  $\alpha$ -synuclein. *Front. Neurol.* **4**, 103 (2013).
220. Griffioen, K. J. *et al.* Dietary energy intake modifies brainstem autonomic dysfunction caused by mutant  $\alpha$ -synuclein. *Neurobiol. Aging* **34**, 928–935 (2013).
221. Fukumitsu, N. *et al.* Reduced [ $^{125}$ I]-metaiodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism. *Nucl. Med. Biol.* **33**, 37–42 (2006).



222. Fukumitsu, N., Suzuki, M., Fukuda, T. & Kiyono, Y. Multipoint analysis of reduced <sup>125</sup>I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. *Nucl. Med. Biol.* **36**, 623–629 (2009).
223. Takatsu, H. *et al.* Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. *J. Nucl. Med.* **41**, 71–77 (2000).
224. Amino, T. *et al.* Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction. *Neurosci. Res.* **60**, 314–318 (2008).
225. Ren, J. *et al.* Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse. *Neurobiol. Aging* **25**, 131–138 (2004).
226. Goldstein, D. S., Li, S. T., Holmes, C. & Bankiewicz, K. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. *J. Pharmacol. Exp. Ther.* **306**, 855–860 (2003).
227. Hallman, H. *et al.* Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. *J. Neurochem.* **44**, 117–127 (1985).
228. Joers, V. *et al.* Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeys. *PLoS ONE* **7**, e35371 (2012).
229. Fleming, S. M. Cardiovascular autonomic dysfunction in animal models of Parkinson's disease. *J. Parkinsons Dis.* **1**, 321–327 (2011).
230. Ariza, D., Sisdelli, L., Crestani, C. C., Fazan, R. & Martins-Pinge, M. C. Dysautonomias in Parkinson's disease: cardiovascular changes and autonomic modulation in conscious rats after infusion of bilateral 6-OHDA in substantia nigra. *Am. J. Physiol. Heart Circ. Physiol.* **308**, H250–H257 (2015).
231. Olanow, C. W. Do prions cause Parkinson disease? The evidence accumulates. *Ann. Neurol.* **75**, 331–333 (2014).  
**This is an excellent review of the possible prion-like contribution to PD pathology.**
232. Klingelhoefer, L. & Reichmann, H. Pathogenesis of Parkinson disease — the gut–brain axis and environmental factors. *Nat. Rev. Neurol.* **11**, 625–636 (2015).  
**This is a comprehensive and up-to-date review of the brain–gut axis.**
233. Lee, H. J., Patel, S. & Lee, S. J. Intravesicular localization and exocytosis of  $\alpha$ -synuclein and its aggregates. *J. Neurosci.* **25**, 6016–6024 (2005).
234. Desplats, P. *et al.* Inclusion formation and neuronal cell death through neuron-to-neuron transmission of  $\alpha$ -synuclein. *Proc. Natl Acad. Sci. USA* **106**, 13010–13015 (2009).
235. Hansen, C. *et al.*  $\alpha$ -Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. *J. Clin. Invest.* **121**, 715–725 (2011).
236. Luk, K. C. *et al.* Pathological  $\alpha$ -synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* **338**, 949–953 (2012).
237. Recasens, A. *et al.* Lewy body extracts from Parkinson disease brains trigger  $\alpha$ -synuclein pathology and neurodegeneration in mice and monkeys. *Ann. Neurol.* **75**, 351–362 (2014).
238. Miwa, H., Kubo, T., Suzuki, A. & Kondo, T. Intragastric proteasome inhibition induces  $\alpha$ -synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats. *Neurosci. Lett.* **401**, 146–149 (2006).  
**This is an important study showing spread of  $\alpha$ -synuclein pathology via the vagus nerve in rats.**
239. Pan-Montojo, F. *et al.* Environmental toxins trigger PD-like progression via increased  $\alpha$ -synuclein release from enteric neurons in mice. *Sci. Rep.* **2**, 898 (2012).
240. Bloch, A., Probst, A., Bissig, H., Adams, H. & Tolnay, M.  $\alpha$ -Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. *Neuropathol. Appl. Neurobiol.* **32**, 284–295 (2006).
241. Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M. & Pearce, R. K. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of  $\alpha$ -synuclein staging. *Neuropathol. Appl. Neurobiol.* **34**, 284–295 (2008).
242. Attems, J. & Jellinger, K. A. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease. *Neuropathol. Appl. Neurobiol.* **34**, 466–467 (2008).
243. Olanow, C. W. & Schapira, A. H. Therapeutic prospects for Parkinson disease. *Ann. Neurol.* **74**, 337–347 (2013).
244. Schapira, A. H. Recent developments in biomarkers in Parkinson disease. *Curr. Opin. Neurol.* **26**, 395–400 (2013).
245. Schapira, A. H., Olanow, C. W., Greenamyre, J. T. & Bezdard, E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. *Lancet* **384**, 545–555 (2014).
246. Schrag, A., Horsfall, L., Walters, K., Noyce, A. & Petersen, I. Prediagnostic presentations of Parkinson's disease in primary care: a case–control study. *Lancet Neurol.* **14**, 57–64 (2015).
247. Berg, D. *et al.* Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. *Lancet Neurol.* **12**, 514–524 (2013).
248. Kasten, M. *et al.* Nonmotor symptoms in genetic Parkinson disease. *Arch. Neurol.* **67**, 670–676 (2010).
249. McNeill, A. *et al.* Hyposmia and cognitive impairment in Gaucher disease patients and carriers. *Mov. Disord.* **27**, 526–532 (2012).
250. Beavan, M. *et al.* Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. *JAMA Neurol.* **72**, 201–208 (2015).
251. Schapira, A. H. & Gegg, M. E. Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. *Proc. Natl Acad. Sci. USA* **110**, 3214–3215 (2013).
252. McNeill, A. *et al.* Amroxolol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. *Brain* **137**, 1481–1495 (2014).
253. Gibb, W. R. & Lees, A. J. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* **54**, 388–396 (1991).
254. Brettschneider, J. *et al.* Spreading of pathology in neurodegenerative diseases: a focus on human studies. *Nat. Rev. Neurosci.* **16**, 109–120 (2015).

## Acknowledgements

A.H.V.S. is supported by a Medical Research Council (MRC) Centre of Excellence in Neurodegeneration grant (MR/L501499/1), a MRC Experimental Medicine programme award (MR/M006646/1) and a grant from Parkinson's UK (G-1403). A.H.V.S. is also supported by the National Institute for Health Research (NIHR) Biomedical Research Centre award to University College London Hospitals.

## Competing interests statement

The authors declare no competing interests.

## Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.